| Excerpt | Reference |
|---|
| "Influenza is a leading cause of morbidity and mortality in the United States, particularly among persons with cardiac and/or pulmonary disease and those over age 65." | ( Betts, RF, 1989) |
| "Type A influenza is more common than Type B in all age groups." | ( Monto, AS, 1983) |
| "Viral infections (influenza) are able to inhibit the hepatic monooxygenase system due to elevated serum interferon levels." | ( Barthel, B; Brockmeyer, NH; Goos, M; Mertins, L, 1998) |
| "Influenza is a worldwide public health issue." | ( Campion, K; Silagy, CA, 1999) |
| "Influenza is an acute respiratory infection associated with raised temperature, headache, muscle ache and cough." | ( Deeks, J; Demicheli, V; Jefferson, T; Rivetti, D, 2000) |
| "Influenza is a highly infectious disease responsible for dangerous epidemics, especially in patients at high risk." | ( Nkoghe, D; Scheen, AJ, 2000) |
| "Influenza is costly for the high risk population who seek physician treatment." | ( Cates, SC; Griffin, AD; Lamb, SC; Mauskopf, JA; Neighbors, DM; Rutherford, C, 2000) |
| "When influenza is circulating within the community, patients with an influenza-like illness who have both cough and fever within 48 hours of symptom onset are likely to have influenza and the administration of influenza antiviral therapy may be appropriate to consider." | ( Colopy, M; Elliott, M; Gravenstein, S; Monto, AS; Schweinle, J, 2000) |
| "Influenza is a major cause of morbidity for people with significant underlying disease, but the impact of influenza on people infected with human immunodeficiency virus (HIV) remains unclear." | ( Elgart, L; Golden, MP; Sajjad, Z, 2001) |
| "Deaths from influenza are recorded every year in the UK and flu epidemics raise concerns for the safety of the young, the elderly and other vulnerable groups in the community." | ( MacConnachie, AM, 1999) |
| "Influenza is a common nosocomial infection." | ( Carman, WF; Kerr, G; Stott, DJ, 2002) |
| "Influenza is common, causing considerable morbidity and sickness absence from work in most winters." | ( Fleming, DM, 2002) |
| "Complications of influenza are a major cause of morbidity and mortality during the influenza season." | ( Ajene, AN; Cole, JA; Cook, SE; Loughlin, JE; Rosenberg, DM; Walker, AM, 2002) |
| "Influenza is responsible for annual epidemics, and is associated with significant morbidity and mortality." | ( Noyola, DE, 2003) |
| "At present, influenza is hardly managed in the community." | ( Balasingam, S; Bossuyt, S; Lambkin, R; Mann, A; Novelli, P; Oxford, JS, 2003) |
| "Influenza is a common illness, affecting many people every winter, with a considerable impact on mortality, hospital admissions, healthcare utilisation and sickness absence from work and school." | ( Fleming, DM, 2003) |
| "Influenza is an important cause of hospitalization due to lower respiratory tract involvement for which there is no specific antiviral treatment with proven efficacy." | ( Elliott, M; Gnann, JW; Hayden, FG; Ison, MG; Nagy-Agren, S; Paya, C; Steigbigel, R; Treannor, J; Weiss, HL, 2003) |
| "Influenza is a serious disease for the elderly." | ( Ikematsu, H, 2003) |
| "(3) When influenza is prevalent in the community patients with the clinical diagnosis of influenza should be treated with neuraminidase inhibitors if the symptoms are lasting not longer than 48 h." | ( Kossow, KD; Lode, H; Ruf, BR; Scholz, H; Vogel, GE; Wutzler, P, 2004) |
| "Influenza is a significant cause of morbidity and mortality worldwide despite extensive research and vaccine availability." | ( Bradbury, JA; Carey, MA; Germolec, DR; Langenbach, R; Seubert, JM; Zeldin, DC, 2005) |
| "(1) Influenza is a common acute respiratory disease due to a virus that causes annual seasonal epidemics." | ( , 2006) |
| "Most children with influenza are treated in the primary care setting, and the cost-effectiveness of influenza vaccination of children has not been fully established." | ( Heikkinen, T; Kilpi, T; Linna, M; Peltola, V; Salo, H; Sintonen, H, 2006) |
| "Influenza is a seasonal viral disease, with the peak of morbidity occurring in Poland between January and March." | ( Brydak, LB; Gawryluk, D; Lietzau, G; Machała, M; Wiatr, E, 2006) |
| "Influenza is a highly contagious respiratory disease associated with substantial morbidity and mortality in vulnerable populations, especially the elderly." | ( González Vidal, D; Puig Barberà, J, 2007) |
| "Influenza is an acute respiratory communicable disease which, during epidemics, can cause high morbidity and mortality." | ( Chen, XY; Duan, X; Liu, GJ; Ni, J; Qiao, JQ; Wang, Q; Wei, J; Wu, TX; Zheng, J; Zhou, LK, 2007) |
| "Influenza is an acute infectious disease which may cause spectacular health, social and economic effects." | ( Brydak, LB; Nitsch-Osuch, A; Wardyn, AK, 2008) |
| "Avian influenza is a disease characterized with severe pneumonia caused by virus influenza A." | ( Altindağ, H; Boga, I; Dogan, N; Kizilkaya, M; Ozkan, B, 2009) |
| "Influenza is a major cause of worldwide morbidity and mortality through frequent seasonal epidemics and infrequent pandemics." | ( Banzhoff, A; Del Giudice, G; Fragapane, E; Groth, N; Pellegrini, M; Podda, A, 2008) |
| "Influenza is a highly contagious and debilitating disease that imposes an excess burden of complications and mortality." | ( Oxford, JS, 2007) |
| "Influenza is a severe, febrile disease of the airways that occurs epidemically in the winter months." | ( Becker, S; Eickmann, M; Kerwat, K; Wulf, H, 2009) |
| "Influenza is often not recognized as an important cause of severe or fatal disease in tropical and subtropical countries in Southeast Asia." | ( Areechokechai, D; Hanshaoworakul, W; Kaewchana, S; Levy, J; Narueponjirakul, U; Sanasuttipun, W; Shinde, V; Simmerman, JM; Ungchusak, K, 2009) |
| "The lethality of influenza is also reduced in mice pretreated with adenovirus carrying the gene for heme oxygenase-1; this benefit may be mediated, at least in part, by the ability of bilirubin to inhibit NADPH oxidase." | ( Barroso-Aranda, J; Contreras, F; McCarty, MF, 2010) |
| "Influenza is a global contagious disease, which causes hundreds of thousands of people deaths." | ( Du, GH; Liu, AL; Wang, HD; Yang, F, 2009) |
| "Influenza is an uncommon illness among premature infants in developed modern neonatal intensive care units (NICUs), but if infants do manifest symptoms of this significant illness, they commonly present with an abrupt onset, with temperature instability and upper respiratory tract involvement and, commonly, clinical features similar to bacterial sepsis." | ( Barak, S; Chulski, E; Kushnir, A; Miron, D, 2010) |
| "H1N1 influenza is an emerging threat that is life threatening to pregnant women in the third trimester." | ( Brown, CM, 2010) |
| "H1N1 influenza is especially dangerous to pregnant women." | ( Brown, CM, 2010) |
| "Antiviral drugs for influenza are now readily available." | ( Dutkowski, R, 2010) |
| "Influenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality." | ( Davies, BE, 2010) |
| "Pregnant women with influenza are at increased risk of morbidity, particularly due to respiratory complications." | ( Donner, B; Hoffmann, G; Niranjan, V, 2010) |
| "The seasonality of influenza is very diverse in tropical countries." | ( Moura, FE, 2010) |
| "Influenza is a disease of global public health significance as evidenced by the 2009 pandemic caused by a novel swine-origin H1N1 virus." | ( Brady, RC, 2010) |
| "Influenza is a major threat to millions of people worldwide." | ( Li, JF; Shen, JS; Xiong, RS; Zhang, Q; Zhao, QJ, 2010) |
| "Influenza is a cause of acute respiratory disease." | ( Amicizia, D; Carloni, R; Cremonesi, I; Schiaffino, S, 2011) |
| "Influenza is a viral disease of the upper respiratory tract, which is manifested in seasonal epidemic waves associated with excess morbidity and mortality." | ( Díez-Domingo, J; Pérez-Vilar, S; Puig-Barberà, J, 2011) |
| "Although influenza is a vaccine-preventable disease that annually causes substantial disease burden, data on virus activity in tropical countries are limited." | ( Al Mamun, A; Azziz Baumgartner, E; Bhuiyan, MU; Bresee, J; Cheng, PY; Dao, CN; Klimov, AI; Luby, SP; Mah-E-Muneer, S; Mounts, A; Nasreen, S; Sharker, MA; Uyeki, TM; Widdowson, MA; Zaman, RU, 2012) |
| "Influenza is an important cause of morbidity and mortality for frail older people." | ( Booy, R; Chiu, CK; Dean, AS; Dobbins, T; Dwyer, DE; Gao, Z; Heron, LG; Lindley, RI; MacIntyre, CR; Moffatt, CR; Philp, DJ; Rosewell, AE; Yin, JK, 2012) |
| "Influenza is an infectious disease caused by RNA viruses of the family Orthomyxoviridae." | ( Acharya, L; Behera, DK; Behera, PM; Dixit, A; Padhi, P, 2012) |
| "Influenza is a common viral infection during pregnancy associated with increased adverse maternal and perinatal outcomes." | ( Cantu, J; Tita, AT, 2013) |
| "Influenza is a communicable acute respiratory infection which, during epidemics, can cause high morbidity and mortality rates." | ( Deng, L; Jiang, L; Wu, T, 2013) |
| "Influenza is a cause of significant morbidity and mortality in young children." | ( Ceyhan, M; Karadag-Oncel, E, 2013) |
| "Influenza is vaccine-preventable; however, the burden of severe influenza in India remains unknown." | ( Chadha, MS; Dawood, FS; Deoshatwar, A; Hirve, S; Juvekar, S; LaFond, KE; Lal, RB; Lele, P; Mishra, AC; Mott, JA; Sambhudas, S, 2013) |
| "Influenza is a leading cause of morbidity and mortality worldwide, with vaccines and antiviral drugs having limited efficacy thus far." | ( García-Sastre, A, 2013) |
| "Influenza is associated with a high mortality and morbidity in older adults." | ( Bigham, M; Brodkin, E; Konrad, S; Krajden, M; Ramler, G; Van Buynder, JL; Van Buynder, PG, 2013) |
| "Burden of Influenza is significantly higher in developing countries as compared to developed countries, but the data on the disease burden is less well defined in most of the developing countries including India, and consequently, constraints evolving strategies for prioritization of measures to prevent and control it." | ( Choudhury, P; Kalra, A; Vashishtha, VM, 2013) |
| "Seasonal influenza is often unsuspected in cirrhotic patients admitted with pneumonia and acute hepatic decompensation." | ( Bal, CK; Bhatia, V; Choudhury, A; Daman, R; Gupta, E; Khillan, V; Kumar, N; Kumar, S; Rathor, N; Saini, D; Sarin, SK, 2014) |
| "H1N1 influenza is a recognized cause of febrile respiratory infection worldwide." | ( Arora, R; Jain, A; Punia, N; Sarda, N; Singhal, S, 2014) |
| "Influenza is an important cause of morbidity and mortality worldwide." | ( Bardin, M; Ginocchio, C; Haffizulla, J; Hartman, A; Hoppers, M; Resnick, H; Rossignol, JF; Samudrala, S, 2014) |
| "Influenza is a serious respiratory disease among immunocompromised individuals, such as the elderly, and its prevention is an urgent social issue." | ( Cueno, ME; Imai, K; Kamio, N; Ochiai, K; Saito, Y; Shimizu, K; Tamura, M, 2015) |
| "Influenza is an acute respiratory illness caused by influenza A and B viruses." | ( Alves da Cunha, AJ; Alves Galvão, MG; Rocha Crispino Santos, MA, 2014) |
| "Influenza is an important cause of annual epidemics of respiratory viral infection associated with significant morbidity and mortality." | ( Ison, MG, 2015) |
| "Influenza is an RNA virus that belongs to the Orthomyxoviridae family." | ( Balakrishnan, A; Chadha, MS; Jadhav, SM; Peter, S; Potdar, VA, 2015) |
| "Influenza is a major cause of substantial morbidity and mortality in humans every year." | ( Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY, 2015) |
| "Influenza is a common disease affecting many children each year." | ( Esposito, S; Principi, N, 2016) |
| "Influenza is an infectious disease that represents an important public health burden, with high impact on the global morbidity, mortality, and economy." | ( Botta, M; de Esch, I; Deodato, D; Edink, E; Fallacara, AL; Gospodova, T; Loregian, A; Mercorelli, B; Nannetti, G; Palù, G; Tintori, C; Trist, IM; Verheij, M; Viteva, L; Wijtmans, M, 2016) |
| "Influenza is a common viral respiratory infection that causes epidemics and pandemics in the human population." | ( Shen, K; Tan, SC; Wu, J; Xiong, T, 2016) |
| "Influenza is a viral infection that affects much of the global population each year." | ( Isakova-Sivak, I; Kiseleva, I; Rudenko, L; Yeolekar, L, 2016) |
| "Data in influenza is lacking." | ( Chan, MCW; Chan, PKS; Cheung, CSK; Choi, KW; Hui, DSC; Kwok, A; Lee, N; Leung, WS; Lui, GCY; Tam, WWS; Tsang, OTY; Wong, CK; Wong, RYK; Yeung, ESL; Yung, IMH, 2017) |
| "Influenza is a worldwide health and financial burden posing a significant risk to the immune-compromised, obese, diabetic, elderly, and pediatric populations." | ( Bajracharya, R; Duan, S; Green, DR; Milasta, S; Morfouace, M; Oluwaseum, AJ; Pasa-Tolic, L; Rezinciuc, S; Roussel, MF; Shelat, A; Shulkin, BL; Smallwood, HS; Thomas, PG; Zink, EE, 2017) |
| "Influenza is a highly contagious respiratory viral infection responsible for up to 50,000 deaths per annum in the US alone." | ( Kadam, RU; Wilson, IA; Wolan, DW; Wright, ZVF; Wu, NC, 2017) |
| "Influenza is a very common infection that is often benign, but sometimes very severe." | ( Allou, N; Allyn, J; Antok, E; Brottet, E; Coolen-Allou, N; Dangers, L; Persichini, R; Roquebert, B; Vandroux, D, 2017) |
| "Influenza is an important health problem due to the mortality it can cause directly or indirectly as well as the complications and the economic and social costs it produces." | ( Eiros, JM; Pérez-Rubio, A, 2018) |
| "Influenza is a severe disease that is highly infectious and can progress to life-threating diseases such as pneumonia or encephalitis when aggravated." | ( Furushima, D; Ide, K; Yamada, H, 2018) |
| "The diagnosis of influenza is important for the implementation of antimicrobial stewardship programs." | ( Ergönül, Ö; Kebapcı, A; Okyay, R; Taymaz, T, 2018) |
| "Influenza is a significant cause of childhood morbidity and death; it contributes to up to 16% of hospitalizations for respiratory illnesses worldwide." | ( Beekmann, SE; Butler, K; Coffin, SE; Cunney, R; Drew, RJ; Kitt, E; Polgreen, P; Zaoutis, T, 2020) |
| "Seasonal influenza is a very common disease." | ( Loperto, I; Nardone, A; Simonetti, A; Triassi, M, 2019) |
| "Influenza is a generally a benign disease, but occasionally it can cause serious complications." | ( Alfayate, S; Couceiro, JA; Cruz-Cañete, M; Launes, C; Otheo, E; Pérez, C; Tagarro, A, 2019) |
| "Influenza is a major public health concern." | ( Dhandapani, P; Hindupur, A; Menon, T, 2019) |
| "Rapid diagnosis of influenza is important for early treatment and institution of control measures." | ( Chan, YF; Chong, YM; Hooi, PS; Lee, LM; Sam, IC; Tan, XH, 2019) |
| "Influenza is one of the most common infectious diseases in travellers, especially in those returning from subtropical and tropical regions." | ( Barisione, G; Bruzzone, B; Butera, F; Grammatico, F; Guarona, G; Murdaca, G; Orsi, A; Schenone, S; Setti, M; Tisa, V, 2019) |
| "Influenza is a highly contagious disease with global annual outbreaks of 3-5 million severe cases and 0." | ( Gattem, S; Madan, A; Nagoji, D; Singh, H; Singh, M; Tanvir, T, 2019) |
| "Influenza is a highly contagious virus that causes seasonal epidemics and unpredictable pandemics." | ( To, J; Torres, J, 2019) |
| "Seasonal influenza is an important cause of morbidity and mortality worldwide." | ( Bellmann-Weiler, R; Fuchs, D; Kurz, K; Pizzini, A; Santifaller, J; Theurl, I; Tschurtschenthaler, C; Weiss, G, 2019) |
| "Influenza is a major cause of morbidity in dialysis patients." | ( Miskulin, DC, 2019) |
| "Influenza is an illness that affects individuals of all ages but its severity varies immensely: from the symptoms of a common cold to the deadly outbreak of the pandemic H1N1 strain in 2009." | ( Eltorki, M; Sharif, S, 2020) |
| "Influenza is a severe disease burden among all age groups." | ( Han, T; Li, X; Liu, C; Yan, L; Yang, B; Yang, J; Yang, X; Zhang, J, 2020) |
| "Seasonal influenza is responsible for approximately 2." | ( Kuentzmann-Klein, P; Martinot, M, 2020) |
| "Influenza is an infectious respiratory illness caused by influenza viruses." | ( Chaisuwirat, P; Ellison, D; Fernandez, S; Macareo, L; Midoeng, P; Rungrojcharoenkit, K; Sunintaboon, P; Ubol, S, 2020) |
| "Influenza is a highly contagious respiratory infection caused by the circulating Swine flu virus." | ( Bhaskar, LVKS; Ratre, YK; Verma, HK; Vishvakarma, NK, 2020) |
| "Influenza is associated with increased morbidity, healthcare costs, hospitalization rates, and mortality in children." | ( Dimopoulou, D; Douros, K; Papaevangelou, V; Pournaras, S; Vourli, S, 2021) |
| "H1N1 influenza is a kind of acute respiratory infectious disease that has a high socioeconomic and medical burden each year around the world." | ( Dong, G; He, W; Wang, C; Wu, Q; Xie, Y; Xu, H; Yan, H; Zhang, W, 2021) |
| "Influenza is a concerning disease in terms of risk management for cruise passengers during a voyage." | ( Amaya Dimas, LDC; Aoki, Y; Kitazawa, K; Mizushiro, N, 2021) |
| "Influenza is mostly associated with the respiratory tract system, especially in the winter season." | ( Kadem, EN; Kutluk, MG, 2021) |
| "Influenza is a highly contagious respiratory virus with clinical impacts on patient morbidity, mortality and hospital bed management." | ( Au Yeung, V; Georgiou, A; Overton, K; Post, JJ; Rawlinson, W; Thapa, K, 2021) |
| "Influenza is a cause of febrile acute respiratory infection (FARI) in India; however, few influenza vaccine trials have been conducted in India." | ( Amarchand, R; Chadha, M; Chokker, R; Choudekar, A; Choudhary, A; Dar, L; Dhakad, S; Gopal, G; Jain, S; Krishnan, A; Kumar, R; Lafond, KE; Lindstrom, S; Narayan, VV; Potdar, V; Saha, S; Widdowson, MA, 2021) |
| "Influenza is an acute viral respiratory disease that can also cause gastroenteritis-like symptoms, such as abdominal pain, nausea, vomiting, and diarrhea." | ( Liu, JY; Wang, HX; Xu, PP; Yu, WD; Zeng, MS, 2021) |
| "Influenza is an infectious disease that leads to an estimated 5 million cases of severe illness and 650,000 respiratory deaths worldwide each year." | ( Du, L; Pang, Y, 2021) |
| "Influenza is one of the most serious respiratory viral infections worldwide." | ( Duangjai, A; Kanchanasurakit, S; Kengkla, K; Rawangkan, A; Saokaew, S, 2021) |
| "Influenza is frequently complicated with bacterial co-infection." | ( Chang, LY; Chen, JM; Chen, LL; Hsing, TY; Huang, LM; Lai, FP; Lee, PI; Lin, HC; Liu, YC; Lu, CY; Yen, TY, 2022) |
| "Index patients with influenza are prescribed a neuraminidase inhibitor and are discharged immediately or transferred to isolation rooms." | ( Chikumi, H; Igari, H; Ishiguro, N; Ito, YM; Iwasaki, S; Kanai, S; Kawamura, H; Koike, R; Miyara, T; Murakami, N; Nagao, M; Nukui, Y; Sano, C; Tokuda, K; Yagi, T; Yamada, K, 2021) |
| "Influenza is one of the most important agents of pandemic outbreak causing substantial morbidity and mortality." | ( Farahmand, B; Forqani, M; Fotouhi, F; Hosseini, SM; Saleh, M; Shokouhi, H; Torabi, A, 2021) |
| "Influenza is associated with excess morbidity and mortality of individuals each year." | ( Carrico, RM; Fry, AM; Furmanek, SP; Hoft, D; Peyrani, P; Ramirez, JA; Wiemken, TL, 2021) |
| "Influenza is an acute respiratory illness caused by the influenza A, B, and C viruses." | ( Bandera, A; Castelli, V; Gori, A; Lombardi, A; Palomba, E; Renisi, G, 2021) |
| "Influenza is prevalent in temperate countries during winter when the environment is dry and cold; however, in tropical and subtropical countries, it is prevalent during the hot, humid rainy season." | ( Daidoji, T; Nakaya, T; Nishioka, K, 2022) |
| "Influenza is a leading cause of community-acquired pneumonia (CAP), and results of influenza tests can direct therapy." | ( Deshpande, A; Haessler, S; Higgins, T; Imrey, PB; Klompas, M; Lindenauer, PK; Pallotta, AM; Rothberg, MB; Yu, PC; Zilberberg, MD, 2022) |
| "Influenza is a century-old disease that continues to baffle humans by its frequently changing nature, seasonal epidemics, and occasional pandemics." | ( Fang, J; Ge, Y; Gu, Z; Hou, D; Mao, L; Sarker, A; Wang, Z; Wei, Z, 2022) |
| "Influenza is a sudden and serious viral breathing and lung-related infectious disease that causes significant deadliness and death worldwide." | ( Duan, N; Li, L; Li, X; Liu, B; Lu, C; Xiong, Y; Zhang, C; Zhang, Y, 2022) |
| "Influenza is an important cause of paediatric illness across the globe." | ( Aik, J; Jamali, N; Loo, LH; Maiwald, M; Seah, A, 2023) |
| "Although seasonal influenza is monitored through a nationwide passive surveillance in Japan, influenza related outcomes and medical resource consumption have not been fully documented." | ( Chaves, SS; Hagiwara, Y; Harada, K; Kimura, T; Nealon, J; Okumura, Y, 2022) |
| "Currently, influenza is managed by vaccination and antiviral drugs such as Amantadine, Rimantadine, Oseltamivir, Peramivir, Zanamivir, and Baloxavir." | ( Oriola, AO; Oyedeji, AO, 2022) |
| "Currently, influenza is managed by vaccination and antiviral drugs such as Amantadine, Rimantadine, Oseltamivir, Peramivir, Zanamivir, and Baloxavir." | ( Oriola, AO; Oyedeji, AO, 2022) |
| "Currently, influenza is managed by vaccination and antiviral drugs such as Amantadine, Rimantadine, Oseltamivir, Peramivir, Zanamivir, and Baloxavir." | ( Oriola, AO; Oyedeji, AO, 2022) |
| "Influenza is a serious public health problem, and its prevalence and spread show significant spatiotemporal characteristics." | ( Feng, Z; Song, Y; Wang, S; Zhang, Y, 2022) |
| "Influenza is a global health concern with millions of infections occurring yearly." | ( Ainslie, KM; Bachelder, EM; Batty, CJ; Carlock, MA; Eckshtain-Levi, M; Hendy, DA; Lifshits, LM; Ontiveros-Padilla, LA; Ross, TM, 2023) |
| "Context: Influenza is a significant respiratory pathogen for residents of long-term care facilities (LTCFs)." | ( Barlow, S; Checovich, M; Hamrick, I; Mundt, M; Reisdorf, E; Temte, J, 2023) |
| "Seasonal influenzas are annually responsible for hundreds of thousands of deaths worldwide, often because of insufficient care, which may depend on orientations of economic policy." | ( Marson, M; Migheli, M; Saccone, D, 2023) |
| "Influenza is a seasonal acute respiratory tract infection with different strains in circulation at different time periods with varying spectrum of clinical presentation." | ( Anbazhagan, J; Chandrasekaran, V; Dhodapkar, R; Philomenadin, FS; Thangaraj, A, 2023) |
| "Influenza is an acute infectious respiratory disease caused by the influenza virus that seriously damages human health, and the essential way to prevent influenza is the influenza vaccine." | ( Fang, B; He, Y; Lu, R; Shen, G; Wan, C; Wu, H; Wu, X; Yang, Y; Zhu, C, 2023) |
| "Swine H1N1/2009 influenza is a highly infectious respiratory disease in pigs, which poses a great threat to pig production and human health." | ( Chen, T; Gao, Q; Li, P; OuYang, A; Ren, C; Suolang, S; Wang, B; Zhang, S; Zhao, Y; Zhou, H; Zou, J, 2023) |
| "Influenza is a contagious respiratory illness that can cause life-threatening complications among high-risk groups." | ( Abdul Aziz, AF; Aljunid, SM; Alkhodary, AA; Azzeri, A; Ismail, A; Mad Tahir, NS, 2023) |
| Excerpt | Reference |
|---|
| "Experience in the field of influenza (vaccination, chemical prevention, clinical pictures, treatment) during the period 1964-1974 is briefly described." | ( Dal Fabbro, G; Frugoni, G, 1975) |
| "For prophylaxis influenza in the infection foci under stationary conditions 213 children were treated with leucocytic interferon with metacyl and 192 children were observed as the control group." | ( Ermol'eva, ZV; Furer, NM; Strutsovskaia, AL; Ulanovskaia, TI, 1975) |
| "The parainfluenza virus was administered 7 days after Hong Kong/68-ts-1 [E] virus infection." | ( Baron, S; Chalhub, EG; Chanock, RM; Murphy, BR; Richman, DD; Uhlendorf, CP, 1975) |
| "The yield of influenza virus from infected primary chick kidney cells (PCKC) was enhanced by treatment with dcAMP." | ( Maassab, HF; Soltysiak, RM, 1977) |
| "The patients with influenza tolerated the treatment well and recovered promptly." | ( Bloom, K; Knight, V; Wilson, RK; Wilson, SZ, 1979) |
| "A live attenuated virus, influenza A/Hong Kong/68(H3N2)-ts-1[E], was administered to 10 normal volunteers." | ( Douglas, RG; Hall, WH; Hyde, RW; Murphy, BR; Richman, D; Zaky, DA, 1976) |
| "During the post-treatment period, while influenza was still prevalent, an accelerated rate of infection occurred among persons previously protected by chemotherapy." | ( Jackson, GG; Muldoon, RL; Stanley, ED, 1976) |
| "Live, attenuated cold-adapted (ca) influenza A/Korea/82 reassortant virus was administered intranasally to all subjects immediately after the second exposure." | ( Bascom, R; Clements, ML; Goings, SA; Green, DJ; Hebel, JR; Kulle, TJ; Sauder, LR, 1989) |
| "In an experimental challenge study of influenza A/Beth/1/85 in 78 subjects of similar age the prophylactic administration of 50 mg, 100 mg or 200 mg/day doses of amantadine were more effective than placebo in preventing influenza illness (P less than 0." | ( Bernstein, DI; Keefer, MC; Reuman, PD; Schiff, GM; Sherwood, JR; Young, EC, 1989) |
| "Two doses of inactivated influenza vaccine containing 15 micrograms of the hemagglutinin of influenza A/Taiwan/1/86(H1N1), A/Leningrad/360/86(H3N2), and B/Ann Arbor/1/86 were administered intramuscularly in the deltoid region 1 month apart." | ( Clements, ML; Dallabetta, GA; Farzadegan, H; Margolick, J; Miotti, PG; Nelson, KE, 1989) |
| "Live, attenuated cold-adapted (ca) influenza A/Korea/82 reassortant virus was administered intranasally to all subjects after the second day of exposure." | ( Clements, ML; Kulle, TJ, 1988) |
| "Treatment with rimantadine of influenza in children and the potential development of resistance in clinical isolates associated with therapy have not been previously studied." | ( Disney, FA; Dolin, R; Francis, AB; Gala, CL; Green, JL; Hall, CB; Madore, PH; Markovitz, DM; Talpey, WB; Zhang, YQ, 1987) |
| "Oral treatment of patients with influenza A or B infection might be possible with ribavirin." | ( Bernstein, DI; Bernstein, JM; Creticos, CM; Hayden, FG; Jackson, GG; Schiff, GM; Stein, DS, 1987) |
| "We treated a woman for influenza pneumonia with respiratory failure at 33 weeks' gestation with oral amantadine and ribavirin inhalation therapy in conjunction with evacuation of the uterus and delivery." | ( Carpenter, RJ; Faro, S; Kirshon, B; Samo, TC; Zurawin, RK, 1988) |
| "In a double-blind study of influenza in a population of college students in 1984, ribavirin small-particle aerosol treatment of 38 patients (18 treated, 20 control) infected with a new antigenic variant, influenza virus strain A/Victoria/7/83 (H1N1), was associated with statistically significant reductions in the height and duration of fever, systemic symptoms, and virus shedding." | ( Couch, RB; Dure, L; Gilbert, BE; Hayes, N; Knight, V; Quarles, JM; Willis, G; Wilson, SZ, 1985) |
| "Ether-treated influenza B haemagglutination inhibition (HI) antigen was used in a study of serum collections from three different epidemic seasons." | ( Kleemola, M; Pyhälä, R; Visakorpi, R, 1985) |
| "In an outbreak of influenza virus A/England/333/80(H1N1) infections in college students, 14 randomly selected patients were treated by inhalation of ribavirin small-particle aerosol through a face mask." | ( Cameron, RW; Couch, RB; Greggs, SE; Knight, V; McClung, HW; Quarles, JM; Waters, BK; Wilson, SZ; Zerwas, JM, 1981) |
| "For antibodies to influenza B viruses the HI tests employing ether-treated antigens were also evaluated." | ( Arangio-Ruiz, G; Donatelli, I; Macchia, T; Mancini, G; Rozera, C, 1983) |
| "Effects of influenza B infection, aspirin treatment and hyperammonemia on the level of free fatty acids, total lipids and triacylglycerols in serum and liver of an animal model of Reye's syndrome are reported here." | ( Deshmukh, DR; Deshmukh, GD; Radin, NS; Shope, TC, 1983) |
| "An intranasal, inactivated trivalent influenza A vaccine containing 7 micrograms of A/Bangkok/1/79 (H3N2) hemagglutinin was administered to 20 children aged 1 to 6 years to assess the local and systemic immune responses to antigen delivered to the respiratory tract." | ( Karzon, DT; Kervina, M; Lawrence, EM; Murphy, BR; Phelan, MA; Wright, PF, 1983) |
| "During an outbreak of influenza A/Brazil/78 H1N1 infection, 47 volunteers with clinical and virological influenza of less than 2 days duration were treated in a randomized double-blind fashion for 5 days with 100 or 200 mg of amantadine daily or with 3." | ( Betts, RF; Douglas, RG; Roth, FK; Younkin, SW, 1983) |
| "Hence, during an influenza outbreak, five days of empirical therapy with amantadine or rimantadine for persons with an influenza-like syndrome should ameliorate clinical symptoms and might decrease spread of virus." | ( Betts, RF; Christmas, WA; Douglas, RG; Hayden, FG; Van Voris, LP, 1981) |
| "The clinical signs and symptoms of influenza and quantitative viral shedding were the same in ribavirin- and placebo-treated groups." | ( Charette, RP; Cooney, MK; Fox, JP; Hall, CE; Smith, CB, 1980) |
| "Consecutive A (H3N2) influenza virus isolates from 2 influenza virus-infected immunodeficient patients treated with amantadine were examined using a novel polymerase chain reaction (PCR)-restriction analysis for resistance to this antiviral compound." | ( Cox, NJ; Hayden, FG; Klimov, AI; Rocha, E; Roumillat, LF; Shult, PA, 1995) |
| "Antibody responses to influenza A/Beijing/32/92 (H3N2) and influenza A/Texas/36/91 (H1N1) in the prednisone-treated and control groups were not different." | ( Baxter, BD; Frank, AL; Jindal, P; Park, CL; Sullivan, M, 1996) |
| "Using a murine respiratory influenza infection model, intranasally administered LIP-IFN-gamma conferred protection to 70% in mice challenged intranasally with 10 LD50 doses of influenza A/PR/8 virus compared with a 20% survival rate using free IFN-gamma." | ( Gorton, L; Kournikakis, B; Saravolac, EG; Wong, JP, 1996) |
| "Coadministration of liposomal influenza vaccine with monophosphoryl lipid A (MPL) resulted in enhanced CD8+ CTL response and IFN-gamma production among old mice (35 and 12,000 times, respectively)." | ( Acuna, C; Caballero, D; Gilbert, B; Harmon, M; Mbawuike, IN; Petribon, P; Pham-Nguyen, K, 1996) |
| "Drug-resistant strains of influenza have been recovered in up to half the subjects undergoing treatment, and prophylaxis may fail in homes where drug is given for both prophylaxis and therapy." | ( Nicholson, KG, 1996) |
| "A trivalent inactivated influenza vaccine, composed of A/Yamagata/32/89 (H1N1), A/Kitakyusyu/159/93 (H2N2) and B/Mie/1/93 influenza virus strains, was administered intranasally together with recombinant LTB containing 1% recombinant LT (LTB*)." | ( Hashigucci, K; Ishidate, T; Kamiya, H; Kurata, T; Tamura, S, 1997) |
| "A total of 417 adults with influenza-like illness of < or =48 hours' duration were randomly assigned to one of three treatments: 6." | ( Aoki, FY; Bohnen, AM; Fleming, DM; Hayden, FG; Hirst, HM; Keene, O; Nicholson, KG; Osterhaus, AD; Treanor, JJ; Wightman, K, 1997) |
| "In adults with influenza A or B virus infections, direct administration of a selective neuraminidase inhibitor, zanamivir, to the respiratory tract is safe and reduces symptoms if begun early." | ( Aoki, FY; Bohnen, AM; Fleming, DM; Hayden, FG; Hirst, HM; Keene, O; Nicholson, KG; Osterhaus, AD; Treanor, JJ; Wightman, K, 1997) |
| "Comparison experiments run versus the influenza A (H1N1) virus-induced infection using GS4104, GS4071 and the neuraminidase inhibitor zanamivir (GG167, 4-guanidino-Neu5Ac2en), all administered p." | ( Bailey, KW; Barnard, DL; Huffman, JH; Kim, CU; Morrison, A; Sidwell, RW; Syndergaard, T; Wong, MH, 1998) |
| "To evaluate the immunogenicity of the influenza virus vaccine in children receiving short-course (a burst) prednisone therapy for acute asthmatic exacerbations." | ( Carter, ER; Carter, PS; Fairchok, MP; Regnery, HL; Trementozzi, DP, 1998) |
| "Zanamivir, a new agent for treating influenza, offers promise but needs further study and approval by the Food and Drug Administration before it can be recommended for routine use." | ( Mossad, SB, 1999) |
| "We assessed the effect of influenza vaccination on plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA and the impact of age, plasma HIV-1 RNA level, CD4 cell count, and anti-HIV therapy on immune response." | ( Chernoff, D; Cox, N; Craven, DE; Fuller, JD; Heeren, TC; Steger, KA, 1999) |
| "A total of 75 phase II subjects with influenza or a history of exposure to naturally occurring influenza virus were administered zanamivir as an intranasal spray (3." | ( Hussey, EK; Moore, KH; Peng, AW, 2000) |
| "We treated two children with influenza-associated acute encephalopathy by a combination of mild hypothermia and steroid pulse therapy." | ( Aihara, Y; Kimura, S; Nezu, A; Ohtsuki, N, 2000) |
| "Demand for the rapid diagnosis of influenza infections has increased with the advent of the availability of neuraminidase antiviral therapy for influenza A and B." | ( Billetdeaux, E; Carroll, K; Dean, G; Fox, L; Gordon, C; Goulding, C; Hindiyeh, M; Johnson, M; Kenyon, B; Langer, J; Morgan, H; Powers, A; Shakib, S; Skodack-Jones, L; Turnbow, A; Vardeny, G; Woolstenhulme, D, 2000) |
| "As prophylaxis against influenza in families, amantadine and rimantadine have had inconsistent effectiveness, partly because of the transmission of drug-resistant variants from treated index patients." | ( Elliot, MJ; Gubareva, LV; Hammond, JM; Hayden, FG; Klein, TC; Monto, AS; Ossi, MJ; Sharp, SJ, 2000) |
| "Fifteen children with influenza type A (H3N2) virus infection (mean age, 38 months) were treated with amantadine." | ( Kimura, K; Komiyama, O; Sugaya, N; Yamamoto, K; Yamazaki, M, 2000) |
| "Early treatment of influenza illness with zanamivir reduced the number of these antibiotic prescriptions." | ( Elliott, M; Hammond, JM; Hayden, FG; Kaiser, L; Keene, ON, 2000) |
| "Defined clinical predictors of an influenza infection can help guide timely therapy and avoid unnecessary antibiotic use." | ( Colopy, M; Elliott, M; Gravenstein, S; Monto, AS; Schweinle, J, 2000) |
| "When influenza is circulating within the community, patients with an influenza-like illness who have both cough and fever within 48 hours of symptom onset are likely to have influenza and the administration of influenza antiviral therapy may be appropriate to consider." | ( Colopy, M; Elliott, M; Gravenstein, S; Monto, AS; Schweinle, J, 2000) |
| "The in-vivo anti-influenza-virus activity of Stachyflin derivatives (III and its phosphate ester, III-Phos), a new class of haemagglutinin fusion inhibitor, and the improvement of their absorption after oral or intranasal administration were studied in mice, rats, and ferrets." | ( Fujioka, T; Fujiwara, T; Hashimoto, N; Hattori, N; Ono, J; Sugimoto, H; Sugita, K; Yagi, S; Yoshimoto, J, 2000) |
| "In the influenza-positive population (n = 1572), significantly more zanamivir-treated patients were rapid resolvers compared with those receiving placebo (807 [72%] vs 765 [64%], P < 0." | ( Monto, AS; Moult, AB; Sharp, SJ, 2000) |
| "Volunteers experimentally infected with influenza A/Texas/36/91 (H1N1) virus and treated with the neuraminidase (NA) inhibitor oseltamivir were monitored for the emergence of drug-resistant variants." | ( Gubareva, LV; Hayden, FG; Kaiser, L; Matrosovich, MN; Soo-Hoo, Y, 2001) |
| "An alternate agent for influenza chemoprophylaxis that is effective against both influenza A and B, is easily administered and has few side effects, could greatly enhance current prevention and control measures and warrants serious assessment." | ( Loewen, N; Parker, R; Skowronski, D, 2001) |
| "Studies in volunteers with experimental human influenza A or B showed that administration of oral oseltamivir 20 to 200 mg twice daily for 5 days reduced both the quantity and duration of viral shedding compared with placebo." | ( McClellan, K; Perry, CM, 2001) |
| "Successful treatment of influenza depends on an accurate diagnosis of the illness and prompt intervention." | ( Hays, J; Keene, O; Newman, R; Webster, A; Zambon, M, 2001) |
| "Individuals at high-risk of influenza have potentially more to gain from zanamivir therapy." | ( Gravenstein, S; Johnston, SL; Loeschel, E; Webster, A, 2001) |
| "In mice infected with influenza A or B viruses, oral treatment with peramivir was highly effective in preventing death, signs of the disease and in lowering lung virus titres." | ( Sidwell, RW; Smee, DF, 2002) |
| "Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999-2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay." | ( Boivin, G; Goyette, N, 2002) |
| "The prevention of influenza virus infections by the use of vaccines remains the most cost-effective and practical method of influenza virus control, but the use of antiviral prophylaxis and treatment in certain populations or high-risk individuals is also possible." | ( Englund, JA, 2002) |
| "However, the optimal influenza prevention and treatment strategy is unknown." | ( Clements, DA; Hamilton, JD; Huber, J; Lee, PY; Matchar, DB; Peterson, ED, 2002) |
| "We diagnosed influenza infection in 2 children receiving maintenance treatment for acute lymphoblastic leukemia." | ( Asano, T; Fukunaga, Y; Hayakawa, J; Maeda, M; Migita, M; Ueda, T, 2002) |
| "Antiviral treatment of influenza without rapid testing is reasonable economically in febrile patients with typical symptoms during influenza season." | ( Roberts, MS; Smith, KJ, 2002) |
| "Further, once an outbreak of influenza occurs in a hospital, administration of anti-influenza drugs to high-risk patients also needs to be considered." | ( Mizuno, Y; Suzuki, K; Torii, M; Yamamoto, T, 2002) |
| "Once a person with a suspected case of influenza was identified (index patient), treatment of all other household members (contacts) > or =5 years old was initiated." | ( Blanckenberg, SJ; Cooper, C; Fleming, DM; Kerr, C; Monto, AS; Pichichero, ME; Ruuskanen, O, 2002) |
| "We compared the outcomes of influenza in 56 patients treated with zanamivir or oseltamivir to a group of 52 influenza patients from the time before these drugs were available." | ( Vogel, GE, 2002) |
| "In two influenza seasons during which H1N1 and H3N2 cocirculated, resistance was more frequent in H3N2 strains than in H1N1 strains after amantadine treatment." | ( Oshitani, H; Saito, R; Sakai, T; Sano, Y; Sato, I; Sato, M; Suzuki, H, 2003) |
| "The potential market for a new influenza treatment is large and the potential role of neuraminidase inhibitors in addressing this market has been covered in several review articles [1-4]." | ( Fleming, DM, 2003) |
| "In adults and adolescents with a proven influenza illness, oseltamivir treatment reduced overall antibiotic use for any reason by 26." | ( Hayden, F; Kaiser, L; Mahoney, P; Mills, T; Ward, P; Wat, C, 2003) |
| "Oseltamivir treatment of influenza illness reduces LRTCs, antibiotic use, and hospitalization in both healthy and "at-risk" adults." | ( Hayden, F; Kaiser, L; Mahoney, P; Mills, T; Ward, P; Wat, C, 2003) |
| "To determine the cost-effectiveness of influenza testing and treatment strategies for older adults." | ( Bellantonio, S; Rose, DN; Rothberg, MB, 2003) |
| "Only the presence of concurrent influenza-like illness was significantly associated with adverse events during amantadine hydrochloride therapy." | ( Campbell, G; Kolbe, F; Papaioannou, A; Sitar, DS, 2003) |
| "Concurrent influenza-like illness is likely to confound attempts to associate adverse reactions to the administration of amantadine hydrochloride therapy." | ( Campbell, G; Kolbe, F; Papaioannou, A; Sitar, DS, 2003) |
| "The etiologic role of influenza in hospitalizations and deaths among persons infected with HIV since the introduction of highly active antiretroviral therapy (HAART) is not known." | ( Coffey, CS; Griffin, MR; Mitchel, EF; Neuzil, KM, 2003) |
| "Yearly administration of the influenza vaccine and/or treatment of influenza with an antiviral (oseltamivir) can significantly decrease the incidence of acute otitis media during influenza season." | ( Owen Hendley, J; Pappas, DE, 2003) |
| "PEP of household contacts of those with influenza reduces the secondary spread of influenza in families when the initial household case is treated." | ( Belshe, R; Carr, J; Dutkowski, R; Hayden, FG; Hughes, C; Lanno, R; Small, I; Villanueva, C; Ward, P, 2004) |
| "During the usual influenza epidemics the main value of neuraminidase inhibitors lies in their use for therapy, prophylaxis and post-exposure prophylaxis in long-term care institutions for the elderly (for prophylaxis only oseltamivir is licensed)." | ( Beyer, WE; de Jong, JC; Fouchier, RA; Osterhaus, AD; Rimmelzwaan, GF, 2004) |
| "During influenza season, our findings support rapid testing for influenza, followed by empiric treatment for anthrax pending blood culture results for those who test negative for influenza." | ( Fine, AM; Fleisher, GR; Fraser, HS; Mandl, KD; Wong, JB, 2004) |
| "We report a 2-year-old child with influenza A encephalitis treated with amantadine who achieved a potentially therapeutic concentration in cerebrospinal fluid." | ( Geskey, JM; Thomas, NJ, 2004) |
| "Laboratory-confirmed influenza infection, symptoms of influenza, drug compliance, and any side-effects from oseltamivir treatment." | ( Chan, PK; Chik, KW; Lee, V; Li, CK; Shing, MM; Tam, JS; Yuen, PM, 2004) |
| "We investigated this clinical sign in influenza virus-infected cotton rats (Sigmodon hispidus) and the efficacy of antiviral and anti-inflammatory therapy in reducing symptomatic disease." | ( Eichelberger, MC; Ottolini, MG; Prince, GA, 2004) |
| "Current means of control for influenza are based on prophylaxis by vaccines and on treatment by the available specific influenza neuraminidase inhibitor drugs." | ( Arnon, R; Ben-Yedidia, T; Jeon, SH; Kayhan, B, 2004) |
| "In Germany, for treating influenza amantadine, oseltamivir and zanamivir are approved." | ( Kossow, KD; Lode, H; Ruf, BR; Scholz, H; Vogel, GE; Wutzler, P, 2004) |
| "Pharmacoeconomic analyses of influenza treatment with oseltamivir in an otherwise healthy Danish adolescent/adult population show that this treatment saves money for society and is associated with a relatively low cost from a health care payer's perspective." | ( Gyldmark, M; Holme Hansen, E; Vindt Holm, M, 2004) |
| "During an influenza outbreak, only patients with influenza or those who have had prophylactic treatment may be admitted to the facility." | ( Cools, HJ; van Essen, GA, 2005) |
| "In the treatment of confirmed influenza, neuraminidase inhibitors yield only a limited reduction in the duration of disease and are neither efficacious nor cost-effective." | ( Bonneux, L, 2005) |
| "Both patients died of influenza A (H5N1) virus infection, despite early initiation of treatment in one patient." | ( Bach, VC; de Jong, MD; Do, QH; Farrar, J; Guan, Y; Nguyen, VC; Peiris, JS; Phan, TQ; Smith, GJ; Tran, TH; Tran, TT; Truong, HK; Vo, MH, 2005) |
| "Patients showing symptoms of influenza were randomly assigned to receive oral oseltamivir 75 mg twice daily for 5 days (oseltamivir group), or symptomatic treatment (control group) within 48 h after symptom onset." | ( Chen, XY; Cui, DJ; Lin, JT; Wang, YZ; Wu, XD; Yu, XZ; Zhu, JH, 2006) |
| "The cost of treating influenza and its complications was comparable between the two groups (p = 0." | ( Chen, XY; Cui, DJ; Lin, JT; Wang, YZ; Wu, XD; Yu, XZ; Zhu, JH, 2006) |
| "The impact of targeted influenza vaccination and antiviral prophylaxis/treatment (oseltamivir) in high risk groups (elderly, chronic diseases), priority (essential professionals), and total populations was compared." | ( Bonmarin, I; Desenclos, JC; Doyle, A; Le Strat, Y; Lévy-Bruhl, D, 2006) |
| "Most children with influenza are treated in the primary care setting, and the cost-effectiveness of influenza vaccination of children has not been fully established." | ( Heikkinen, T; Kilpi, T; Linna, M; Peltola, V; Salo, H; Sintonen, H, 2006) |
| "Emergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) develops at a low level following drug treatment, and person-to-person transmission of resistant virus has not been recognized to date." | ( Aymard, M; Hampson, AW; Hay, A; Hayden, FG; Klimov, A; Macken, C; McKimm-Breschkin, JL; Monto, AS; Tashiro, M; Webster, RG; Zambon, M, 2006) |
| "Oseltamivir is less effective for influenza B than for influenza A with regard to duration of fever and virus persistence, irrespective of patient age or the timing of administration of the first dose." | ( Hirotsu, N; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Maeda, T; Satoh, I, 2006) |
| "The goals of antiviral treatment for influenza are to decrease symptoms and functional disability and, more important, to decrease associated complications, hospitalizations, and mortality." | ( Hayden, FG; Pavia, AT, 2006) |
| "A few oseltamivir-resistant influenza B strains were isolated before the start of oseltamivir therapy." | ( Hatakeyama, S; Ichikawa, M; Ito, M; Kawakami, C; Kawaoka, Y; Kimura, K; Kiso, M; Mitamura, K; Sugaya, N; Tamura, D; Yamazaki, M, 2007) |
| "The lack of a virologic diagnosis of influenza, and an index date based on the first diagnosis of influenza rather than first exposure or symptom onset, may have resulted in a conservative estimate of treatment effect." | ( Barr, CE; Bradley, JS; Iacuzio, D; Schulman, K, 2007) |
| "Treatment for influenza also includes prescription antiviral agents and vaccines for prevention." | ( Jurenka, J; Roxas, M, 2007) |
| "The long history of influenza drug development has both contributed practical advances in antiviral chemotherapy and improved the understanding of influenza pathogenesis and epidemiology." | ( Hayden, FG; Ong, AK, 2007) |
| "Following tri-valent influenza vaccination, a similar rise in antibody titer occurred in sirolimus and calcineurin inhibitor (CNI) treated patients, though sirolimus treated patients developed a 'protective' titer to more influenza antigens." | ( Chaudhry, AN; Doffinger, R; Ojha, S; Smith, JC; Smith, KG; Watson, CJ; Willcocks, LC, 2007) |
| "The lack of a virologic diagnosis of influenza, and an index date based on the first diagnosis of influenza rather than first exposure or symptom onset, may have resulted in a conservative estimate of treatment effect." | ( Blumentals, WA; Schulman, KL, 2007) |
| "Secondary complications of influenza, such as respiratory disease and otitis media, were reduced in patients treated with oseltamivir." | ( Blumentals, WA; Schulman, KL, 2007) |
| "Presence of influenza A virus was demonstrated in 24 subjects: seven out of eight in the treatment group, 12 of 42 in the prophylaxis group and all five in the no-oseltamivir group." | ( Chang, YM; Chen, CH; Cheng, YH; Chiang, SL; Huang, CG; Huang, CT; Huang, YC; Li, WC; Tsao, KC; Yang, SY, 2008) |
| "We diagnosed her as having influenza type A virus-associated encephalopahty and treated her with Oseltamivir, methylprednisolone pulse therapy, and a high dose of intravenous immunoglobulins." | ( Hozumi, I; Inuzuka, T; Kimura, A; Ogura, S; Sakurai, T; Tanaka, Y, 2007) |
| "For the treatment of influenza in general and for pandemic avian influenza, the MegaRibavirin-Aerotech II method of aerosol treatment allows for short treatment periods, minimizes environmental issues and costs less." | ( Gilbert, BE; McLeay, MT, 2008) |
| "Among 1,848 patients screened, 299 influenza A and 209 influenza B patients were administered oseltamivir (treated groups), and 28 influenza A and 66 influenza B patients were assigned as non-treated groups." | ( Gejyo, F; Li, D; Oguma, T; Saito, R; Sakai, T; Sasaki, A; Sato, I; Sato, M; Shobugawa, Y; Suzuki, H; Suzuki, Y; Tanabe, N; Tsukada, H, 2008) |
| "Resistance to adamantanes for treating influenza A(H3N2) has increased dramatically, worldwide, over the past 5 years." | ( Chan, PK; Lam, WY; Ngai, KL; Tang, JW; Wong, JC, 2008) |
| "At the end of the 2003-4 influenza season, we conducted a cross sectional on-line survey of physician knowledge, attitudes and practices regarding rapid diagnostic testing and use of antiviral therapy for influenza at two large academic medical centers, one in Massachusetts and the other in Texas." | ( Bonner, AB; Rajab, MH; Rose, DN; Rothberg, MB; Stechenberg, BW, 2008) |
| "For the treatment of influenza virus infections, neuraminidase inhibitors (NAIs) that prevent the release of virus particles have been effective against most influenza strains." | ( Cheng, YS; Fang, JM; Jeng, KS; Shie, JJ; Su, CY; Temperton, NJ; Wang, SY; Wong, CH, 2008) |
| "Oseltamivir is an inhibitor of influenza virus neuraminidase, which is approved for use for the treatment and prophylaxis of influenza A and B virus infections." | ( Cunningham, F; Davey, RT; Deyton, LR; Goetz, MB; Holodniy, M; Lee, KK; Lin, ET; Olivo, N; Penzak, SR; Raisch, DW; Straight, TM, 2008) |
| "In the advent of an influenza virus pandemic it is likely that the administration of antiviral drugs will be an important first line of defence against the virus." | ( Sugrue, RJ; Sutejo, R; Tan, BH; Yeo, DS, 2008) |
| "We describe a case of influenza virus reactivation, after remission had been achieved with standard oseltamivir therapy, in a patient undergoing nonmyeloablative bone marrow transplantation (NMBMT)." | ( Kimura, F; Kobayashi, A; Kobayashi, S; Motoyoshi, K; Sato, K, 2008) |
| "In an oseltamivir-resistant influenza A/H3N2 virus isolated from an immunocompromised child after 107 days of cumulative treatment, the NA gene contained 3 aa substitutions (N146K, S219T, and A272V) and a 4-aa deletion (Del245-248); reversion mutation experiments using recombinant NA proteins determined that the deletion was the sole change responsible for resistance to oseltamivir." | ( Abed, Y; Baz, M; Boivin, G, 2009) |
| "Antiviral agents for the treatment of influenza are urgently needed to circumvent the limitations of current drugs in several critical areas: high frequencies of resistance to M2 inhibitors among currently circulating strains and variable frequencies of resistance to oseltamivir among A(H1N1) strains, limited efficacy of treatment and treatment-emergent antiviral resistance in cases of avian influenza A(H5N1) illness in humans, and lack of parenteral agents for seriously ill patients." | ( Hayden, F, 2009) |
| "In a nasal vaccine against influenza, the activation of natural killer T (NKT) cells by intranasal coadministration of alpha-galactosylceramide (alpha-GalCer) can potently enhance protective immune responses." | ( Hase, K; Hasegawa, H; Ichinohe, T; Jiang, X; Kamijuku, H; Mori, K; Nagata, Y; Odagiri, T; Ohno, H; Sata, T; Seino, KI; Shimaoka, T; Taniguchi, M; Tashiro, M; Tashiro, T; Yonehara, S, 2008) |
| "Oseltamivir, a specific influenza neuraminidase inhibitor, is an effective treatment for seasonal influenza." | ( Bermingham, A; Democratis, J; Ellis, J; Lackenby, A; McNally, T; Nicholson, K; Pareek, M; Smith, J; Stephenson, I; Zambon, M, 2009) |
| "Persistent influenza virus replication during antiviral therapy in patients undergoing hematopoietic stem cell transplantation (HSCT) could promote the emergence of antiviral drug resistance." | ( Cohen-Daniel, L; Dorozhko, M; Greenbaum, E; Mador, N; Resnick, IB; Shapira, MY; Wolf, DG; Zakay-Rones, Z, 2009) |
| "Antibody response to the inactivated influenza vaccine is not well described in kidney transplant recipients administered newer, but commonly used, immunosuppression medications." | ( Birdwell, KA; Byrne, DW; Ikizler, MR; Ikizler, TA; Sannella, EC; Wang, L; Wright, PF, 2009) |
| "The cost-effectiveness of treating influenzalike illness (ILI) with oseltamivir in the United States was assessed." | ( Brogan, AJ; Sander, B; Talbird, SE; Winiarski, AP, 2009) |
| "Although influenza vaccine can prevent influenza virus infection, the only therapeutic options to treat influenza virus infection are antiviral agents." | ( Jacobson, RM; Ovsyannikova, IG; Poland, GA, 2009) |
| "Treatment and prophylaxis against influenza have been successful using antiviral medications such as adamantanes and neuraminidase inhibitors." | ( Holodniy, M; Schirmer, P, 2009) |
| "In the Netherlands, influenza specific antivirals are used for the therapy of influenza in nursing homes and hospitals, for prophylaxis in high risk groups and neuraminidase inhibitors are stockpiled as part of pandemic preparedness plans." | ( Dijkstra, F; Jonges, M; Koopmans, M; Meijer, A; van der Lubben, IM; Verhoef, L, 2009) |
| "Human cases of oseltamivir-resistant influenza A H1N1 virus emerging in 2007-2008 in Luxembourg were not associated with treatment, prophylaxis or stockpiling of oseltamivir." | ( Even, J; Gerloff, N; Gregory, V; Hau, P; Huberty-Krau, P; Kremer, J; Lackenby, A; Mossong, J; Muller, CP; Opp, M; Schneider, F, 2009) |
| "Monovalent 2009 influenza A (H1N1) MF59-adjuvanted vaccine generates antibody responses likely to be associated with protection after a single dose is administered." | ( Clark, TW; Dillon, H; Groth, N; Hoschler, K; Nicholson, KG; Pareek, M; Stephenson, I, 2009) |
| "The new swine-origin influenza A (H1N1) strain (S-OIV) pandemia may expose immunodepressed cancer patients under chemotherapy to an increased risk of mortality." | ( Barrière, J; Coindard, G; Cua, E; Otto, J; Peyrade, F, 2009) |
| "In hospitalized patients with severe influenza treated with oseltamivir, mortality and length of stay are significantly reduced, and viral load is reduced more quickly than in untreated patients." | ( Ariano, RE; Smith, JR; Toovey, S, 2010) |
| "Along with influenza vaccines, the world is currently almost completely dependent on two licensed drugs for the treatment or prevention of seasonal (influenza A and B viruses) and pandemic influenza (influenza A viruses)." | ( Barr, IG; Holien, JK; Hurt, AC; Parker, MW, 2009) |
| "Recently, in preparation for the influenza A (H1N1) 2009 pandemic, Health Canada published an interim order permitting the expanded use of oseltamivir for treatment or prophylaxis for children younger than 1 year of age." | ( Carleton, B; Goldman, RD; Jain, R; Jamieson, B, 2009) |
| "Oseltamivir, a treatment for influenza, has been shown to decrease the severity of an influenza episode, but few data exist regarding its potentially protective effect against recurrent vascular outcomes among influenza patients with a history of vascular disease." | ( Casscells, SW; Cottrell, L; Granger, E; Kress, AM; Linton, A; Madjid, M, 2009) |
| "The clinical presentation of influenza and outcome of oseltamivir treatment in infants <1 year was similar to that previously reported in older children, but mild gastrointestinal symptoms were common." | ( Siedler, K; Skopnik, H, 2010) |
| "In the current influenza A (H1N1) pandemia, data on neonatal and maternal Oseltamivir chemoprophylaxis and treatment are limited." | ( Dembinski, J, 2010) |
| "Following the explosion of the influenza A pandemic (H1N1) during the first semester of 2009, oseltamivir and zanamivir were used as the treatment of choice in the absence of rigorous clinical studies demonstrating their efficacy in the treatment and prophylaxis of this disease." | ( Lecumberri, J; Montané, E; Pedro-Botet, ML, 2011) |
| "A pandemic influenza A/H1N1v strain with the neuraminidase H274Y mutation was detected in nasal secretions of a 2-year-old leukemic patient with influenza-like illness after 18 days of treatment with oseltamivir." | ( Baldanti, F; Campanini, G; Donatelli, I; Facchini, M; Locatelli, F; Minoli, L; Percivalle, E; Piralla, A; Puzelli, S; Rovida, F, 2010) |
| "Therefore, the effectiveness of influenza antiviral therapy during chronic ethanol consumption remains in question." | ( Coleman, RA; Cook, RT; Langlois, RA; Legge, KL; Meyerholz, DK; Waldschmidt, TJ, 2010) |
| "We describe laboratory-confirmed influenza A pandemic (H1N1) 2009 in 17 hospitalized recipients of a hematopoietic stem cell transplant (HSCT) (8 allogeneic) and in 15 patients with malignancy treated at 6 Australian tertiary centers during winter 2009." | ( Buising, KL; Cheng, AC; Denholm, JT; Doyle, JS; Dwyer, DE; Ferguson, PE; George, B; Harper, JM; Harrison, SJ; Hurt, AC; Johnson, PD; Langan, K; Morrissey, CO; Reid, AB; Seymour, JF; Slavin, M; Thursky, K; Tramontana, AR; Wang, B; Worth, LJ, 2010) |
| "During the last two influenza seasons, one of the predominant influenza A types (H1N1) has developed complete resistance to oseltamivir, the primary treatment option." | ( Lundgren, J; Madsen, L; Nielsen, A, 2010) |
| "Among children with influenza A, oseltamivir treatment started within 24 hours shortened the median time to resolution of illness by 3." | ( Heikkinen, T; Heinonen, S; Ikonen, N; Lehtinen, P; Puhakka, T; Silvennoinen, H; Vahlberg, T; Vainionpää, R; Ziegler, T, 2010) |
| "The use of a rapid test for seasonal influenza enabled the targeted treatment with oseltamivir, as well as a reduction in antibiotic treatment, in patients found positive for influenza in our clinical setting." | ( Barbas, SG; Falagas, ME; Rafailidis, PI; Spiropoulos, T; Theocharis, G; Vouloumanou, EK, 2010) |
| "First-line treatment of influenza A 2009 H1N1 relies on neuraminidase inhibitors such as oseltamivir." | ( Bender, JM; Couturier, BA; Hanson, KE; Pavia, AT; Schwarz, MA; She, RC, 2010) |
| "Two critically ill women with 2009 H1N1 influenza A treated with compassionate-use intravenous peramivir administered as a daily infusion of 600 mg over 30 minutes while receiving continuous venovenous hemodiafiltration (CVVHDF), a form of CRRT." | ( Bauer, KA; Bazan, JA; Firstenberg, MS; Goff, DA; Hollister, AS; Mangino, JE; Reed, EE; Shidham, G, 2010) |
| "Therapy was begun with oseltamivir for influenza infection and intravenous infusions of betamethasone and aminophylline with non-invasive pulmonary ventilation for asthma exacerbation and acute respiratory failure." | ( Ando, K; Asai, N; Iwasaki, T; Kaneko, N; Komatsu, A; Matsunuma, R; Misawa, M; Nakashima, K; Ohkuni, Y; Otsuka, Y; Yasui, D, 2011) |
| "Treatment of seasonal influenza viral infections using antivirals such as neuraminidase inhibitors (NAIs) has been proven effective if administered within 48h post-infection." | ( Beauchemin, CA; Davies, BE; Dobrovolny, HM; Gieschke, R; Jumbe, NL, 2011) |
| "Diagnosing influenza at an early stage of illness is important for the initiation of effective antiviral treatment." | ( Heikkinen, T; Heinonen, S; Lehtinen, P; Silvennoinen, H; Vainionpää, R, 2011) |
| "The first case of pandemic influenza A (H1N1) virus infection in Macau Special Administrative Region (SAR) of the People's Republic of China was documented on June 18, 2009." | ( Fan, YM; Li, TM; Liu, XQ; Zhou, BT, 2010) |
| "Oseltamivir-resistant influenza viruses were isolated from 4 children (3 influenza A [H3N2] and 1 influenza B virus): before the initiation of antiviral therapy in 2 patients and during therapy in the other 2 patients." | ( Adderson, EE; Caniza, M; Carr, S; Franks, J; Govorkova, EA; Ilyushina, NA; Webster, RG, 2011) |
| "Oseltamivir-resistant influenza viruses can exist before or rapidly emerge during antiviral therapy in immunocompromised individuals, and this has important implications for therapy and infection control." | ( Adderson, EE; Caniza, M; Carr, S; Franks, J; Govorkova, EA; Ilyushina, NA; Webster, RG, 2011) |
| "In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy." | ( Andreoletti, L; Blanchon, T; Bouscambert-Duchamp, M; Charlois-Ou, C; Duval, X; Enouf, V; Leport, C; Lina, B; Mentré, F; Mosnier, A; Tibi, A; Tubach, F; van der Werf, S; Vincent, C, 2010) |
| "Since alternative treatment options for influenza are rare, we conclude that the nasal spray containing iota-carrageenan is an alternative to neuraminidase inhibitors and should be tested for prevention and treatment of influenza A in clinical trials in humans." | ( Beer, M; Fazekas, T; Frank-Gehrke, B; Graf, P; Grassauer, A; Kalthoff, D; König-Schuster, M; Leibbrandt, A; Meier, C; Pflugfelder, B; Prieschl-Grassauer, E; Unger, H; Weinmüllner, R, 2010) |
| "Trivalent influenza subunit vaccine was administered to 46 RA patients and to 16 healthy controls." | ( Amir, S; Arad, U; Caspi, D; Elkayam, O; Mandelboim, M; Mendelson, E; Paran, D; Sarbagil-Maman, H; Tzadok, S; Wigler, I, 2011) |
| "Cellular immunity to influenza vaccination in RTX-treated patients was similar to DMARDs-treated patients and healthy controls, while humoral immunity was severely impaired." | ( Amir, S; Arad, U; Caspi, D; Elkayam, O; Mandelboim, M; Mendelson, E; Paran, D; Sarbagil-Maman, H; Tzadok, S; Wigler, I, 2011) |
| "Early demonstration of H1N1 influenza virus and commencing antiviral therapy promptly can be life saving particularly in immunosuppressed patients." | ( Aki, Z; Altindal, S; Güzel, Ö; Senol, E; Sucak, G; Suyani, E, 2011) |
| "In oseltamivir- or zanamivir-treated influenza patients who were statistically comparable in their age distribution, vaccination history, and type or subtype of virus isolates, the virus-shedding period in zanamivir-treated patients was significantly shorter than that in oseltamivir-treated patients." | ( Ichikawa, M; Kawakami, C; Kawakami, E; Kawaoka, Y; Kiso, M; Mitamura, K; Ozawa, M; Shimizu, H; Sugaya, N; Takano, R; Tamura, D; Uehara, R; Yamazaki, M, 2011) |
| "The 2009 H1N1 influenza pandemic prompted the US Food and Drug Administration (FDA) to issue an emergency use authorization (EUA) for the intravenous antiviral peramivir, an unapproved neuraminidase inhibitor (NAI) currently under development." | ( Hollister, AS; Sheridan, WP, 2011) |
| "During the first year of the influenza A(H1N1) 2009 pandemic, unprecedented amounts of the neuraminidase inhibitors, predominantly oseltamivir, were used in economically developed countries for the treatment and prophylaxis of patients prior to the availability of a pandemic vaccine." | ( Barr, IG; Caldwell, N; Deng, YM; Dwyer, DE; Ernest, J; Freeman, K; Hurt, AC; Iannello, P; Kelso, A; Komadina, N; Leang, L; Lin, RT; Shaw, R; Smith, D; Tramontana, AR, 2011) |
| "Breast cancer patients received influenza vaccination during FEC (5-fluorouracil, epirubicin and cyclophosphamide)-containing chemotherapy regimens." | ( Beeker, A; Biesma, DH; de Weerdt, O; Los, M; Meerveld-Eggink, A; Nijziel, MR; Rijkers, GT; Rimmelzwaan, GF; Stouthard, JML; van Beek, R; van der Velden, AMT; van der Velden, AWG; Westerman, M, 2011) |
| "Sixteen patients (76%) were influenza PCR-positive on day 7 after the start of antiviral treatment." | ( Ellermann-Eriksen, S; Gubbels, S; Ilkjær, S; Jensen-Fangel, S; Keld, DB; Lindskov, C; Petersen, E, 2011) |
| "At present, four anti-influenza agents have been approved by the FDA for the treatment of influenza, including two M2 protein ion channel inhibitors-amantadine and rimantadine and two neuraminidase inhibitors-zanamivir and oseltamivir." | ( Li, JF; Shen, JS; Xiong, RS; Zhang, Q; Zhao, QJ, 2010) |
| "Drugs inhibiting the influenza A virus (IAV) neuraminidase (NA) are the cornerstone of anti-IAV chemotherapy and prophylaxis in man." | ( Bailey, AL; Bennink, JR; Das, SR; Gibbs, JS; Hensley, SE; Schmidt, LM; Yewdell, JW, 2011) |
| "Here, according to the guideline of the influenza encephalopathy, I wrote the utility of the steroid treatment(methylprednisolone pulse therapy) in the disease." | ( Mori, M, 2011) |
| "During the 2009 influenza A(H1N1) pandemic, the Food and Drug Administration granted emergency use authorization of IV neuraminidase inhibitors for hospitalized patients with influenza, creating a need for rapid decision analyses to help guide use." | ( Bailey, RR; Lee, BY; McGlone, SM; Smith, KJ; Tai, JH; Wiringa, AE; Zimmer, SM; Zimmerman, RK, 2011) |
| "All those with 2009 H1N1 influenza and 89% of those without were treated with oseltamivir." | ( Anderson, BL; Fitzsimmons, C; Rouse, DJ, 2011) |
| "We conclude that influenza vaccination should be recommended to cancer patients treated with sunitinib or sorafenib." | ( de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC, 2011) |
| "Zanamivir (ZA) is a potent anti-influenza drug, but it cannot be administrated orally because of the hydrophilic carboxylate and guanidinium groups." | ( Cheng, YS; Fang, JM; Lee, PS; Liu, KC; Wang, SY; Wong, CH, 2011) |
| "She was diagnosed as influenza A and was treated with zanamivir hydrate (10 mg/day, inhalation)." | ( Hirayama, T; Ikeda, K; Ito, H; Iwasaki, Y; Kano, O; Kawabe, K; Nakamura, Y; Yoshii, Y, 2011) |
| "Neuraminidase (NA) inhibitors used for influenza therapy are believed to prevent the release of progeny virus from the surface of an infected cell." | ( Ohuchi, M; Ushirogawa, H, 2011) |
| "Comparative pharmacokinetics of anti-influenza drug composition Antigrippin-maximum administered in capsules and a powder for preparing solutions has been studied after single administraton in a group of 18 healthy volunteers." | ( Belolipetskaia, VG; Belolipetskiĭ, NA; Blagodatskikh, SV; Guranda, DF; Kibalchich, DA; Rudenko, LI; Zhabina, EA, 2011) |
| "Drugs for the treatment of influenza inhibit the ion channel M(2) protein or the enzyme neuraminidase." | ( Razonable, RR, 2011) |
| "We identified 1257 children with influenza infection, 264 of whom were treated with oseltamivir within 24 hours of hospital admission." | ( Coffin, SE; Hall, M; Keren, R; Leckerman, K; Localio, R; Zaoutis, TE, 2011) |
| "The 2009 influenza pandemic led to guidelines emphasizing antiviral treatment for all persons hospitalized with influenza, including pregnant women." | ( Arnold, K; Baumbach, J; Bennett, NM; Doshi, S; Finelli, L; Fry, AM; Gershman, K; Hancock, EB; Kamimoto, L; Lynfield, R; Morin, C; Perez, A; Reingold, A; Ryan, P; Schaffner, W; Thomas, A; Yousey-Hindes, K; Zansky, S, 2011) |
| "Of 5943 adults hospitalized with influenza in prepandemic seasons, 3235 (54%) received antiviral treatment, compared with 4055 (82%) of 4966 during the pandemic." | ( Arnold, K; Baumbach, J; Bennett, NM; Doshi, S; Finelli, L; Fry, AM; Gershman, K; Hancock, EB; Kamimoto, L; Lynfield, R; Morin, C; Perez, A; Reingold, A; Ryan, P; Schaffner, W; Thomas, A; Yousey-Hindes, K; Zansky, S, 2011) |
| "Of 56 infants with definite influenza (35 pandemic H1N1 2009) admitted to the CHW, 20 were treated with oseltamivir." | ( Booy, R; Dwyer, DE; Elliott, EJ; Heron, L; Kesson, A; Khandaker, G; Lester-Smith, D; Zurynski, Y, 2011) |
| "Of 210 patients with suspected influenza who underwent respiratory virus reverse transcription polymerase chain reaction (RT-PCR) testing, 113 (54%) received empiric oseltamivir therapy." | ( Aziz, M; Aziz, Z; Eltoukhy, N; Patel, S; Singh, K; Vasoo, S, 2012) |
| "The short-term influenza-specific effector B cell response was also significantly decreased in RA patients treated with anti-TNF as compared with healthy controls, and correlated with decreased influenza-specific memory B cells and serum antibody present at one month following vaccination." | ( Anandarajah, AP; Anolik, JH; Barnes, M; Bryk, P; Coca, A; Feng, C; Kobie, JJ; Lee, FE; Looney, RJ; Ritchlin, CT; Rosenberg, AF; Sanz, I; Tabechian, DA; Thiele, RG; Treanor, JJ; Wei, C; Zheng, B, 2011) |
| "To increase knowledge about pandemic influenza in children with leukemia and better understand the risk factors for severe disease, we have presented the clinical characteristics of 8 children with acute leukemia and pandemic influenza treated at our center." | ( Azik, F; Culha, V; Kara, A; Tavil, B; Tezer, H; Tunç, B; Yaral, N, 2012) |
| "Pandemic influenza A H1N1/2009 vaccine response is diminished in SLE under immunosuppressive therapy and antimalarials seems to restore this immunogenicity." | ( Aikawa, NE; Bonfa, E; Borba, EF; Calich, AL; Costa, LP; Fuller, R; Goncalves, CR; Guedes, LK; Ishida, MA; Leon, EP; Moraes, JC; Oliveira, SA; Pasoto, SG; Precioso, AR; Ribeiro, AC; Saad, CG; Silva, CA, 2012) |
| "2009 A(H1N1)v influenza was not associated with worse outcomes in hospitalized pregnant women compared with non-pregnant ones of reproductive age in a context of early diagnosis and antiviral therapy." | ( Carratalá, J; Fariñas, MC; García-Gasalla, M; Leyes, M; López-Medrano, F; Martínez-Sánchez, N; Ortega, L; Oteo, JA; Pachón, J; Paño-Pardo, JR; Pumarola, T; Rodríguez-Baño, J; Segura, F; Torre-Cisneros, J; Viasus, D, 2012) |
| "Given the serious health threat of influenza at all ages and limitations in vaccine delivery, peramivir is a promising addition to the currently limited treatment options for the treatment of severe influenza infection." | ( Peek, LA; Shetty, AK, 2012) |
| "During influenza epidemics, empirical antiviral treatment appears to be a cost-effective strategy in managing patients hospitalized with severe respiratory infection suspected of influenza, from the perspective of healthcare providers in Hong Kong." | ( Chan, ES; Ip, M; Lee, NL; Leung, MY; You, JH, 2012) |
| "In response to the influenza A(H1N1)pdm09 (pH1N1) pandemic, peramivir, an investigational intravenous neuraminidase inhibitor, was made available for treatment of hospitalized patients with pH1N1 in the United States under an Emergency Use Authorization (EUA)." | ( Garg, S; Kim, HJ; Merlin, T; Patel, A; Redd, S; Uyeki, TM; Yu, PA; Yu, Y, 2012) |
| "Treatment of influenza with oseltamivir 1." | ( Hosoya, M; Ihara, T; Kumagai, T; Morioka, I; Morishima, T; Nonoyama, S; Okabe, N; Okada, K; Sugaya, N; Tanaka-Taya, K; Ueta, I, 2012) |
| "Oseltamivir resistance in A(H1N1)pdm09 influenza is rare, particularly in untreated community cases." | ( Barr, IG; Booy, R; Caldwell, N; Dalton, C; Deng, YM; Dixit, R; Durrheim, D; Dwyer, DE; Gehrig, N; Givney, RC; Hardie, K; Hurt, AC; Iannello, P; Kelso, A; Leang, SK; Lee, RT; Levy, A; Maurer-Stroh, S; Merritt, T; Osbourn, M; Shaw, R; Smith, DW; Wang, B; Wark, P; Wilson, NJ; Xue, L, 2012) |
| "Our data indicate that influenza subtyping in combination with baseline viral load measurements might help to optimize the duration of antiviral therapy in the individual child." | ( Duwe, S; Karsch, K; Louis, F; Muehlhans, S; Rath, B; Schweiger, B; Skopnik, H; Tief, F; Tuerk, E; von Kleist, M, 2012) |
| "Weekly prescription utilization of all influenza antivirals used to treat influenza during the seasonal influenza outbreak followed the same trend of weekly reports of the number of visits for influenza-like-illnesses (ILI) by the Influenza Sentinel Provider Surveillance Network." | ( Borders-Hemphill, V; Mosholder, A, 2012) |
| "Patients were assessed for influenza infection via daily diary, every-other-week culture and PCR, and baseline and end-of-treatment serology." | ( Dutkowski, R; Ison, MG; Kriván, G; Nist, A; Shapira, MY; Szakaly, P, 2012) |
| "Oral antiviral agents to treat influenza are challenging to administer in the intensive care unit (ICU)." | ( Acosta, M; Louie, JK; Schechter, R; Uyeki, TM; Yang, S; Yen, C, 2012) |
| "We used Avian Influenza Registry data from 10 countries to examine the risk of death in 215 patients with confirmed H5N1 infection who were treated with oseltamivir, according to viral clade, age, respiratory failure, and adjunctive treatment with corticosteroids or antibiotics." | ( Adisasmito, W; Bamgboye, E; Chan, PK; Coker, R; Dogan, N; Dreyer, NA; Gasimov, V; Hanshaoworakul, W; Lee, N; Oner, AF; Phommasack, B; Swenson, A; Toovey, S; Touch, S; Tsang, O; Zaman, M, 2012) |
| "All the 61 influenza virus isolates (43 before enrollment, 18 during treatment) proved to be sensitive to zanamivir." | ( Cao, B; Chen, BY; Dong, JP; Gao, Y; Hu, K; Li, XL; Pu, ZH; Shu, YL; Song, SF; Wang, C; Wang, DY; Wang, J; Wei, LQ; Xu, Q; Yu, XM; Yu, YS, 2012) |
| "With the recent influenza A/H1N1 2009 pandemic still spreading through global populations, there has been an increased focus on optimizing the prevention, diagnosis and treatment of influenza infections, as well as the epidemiology of the virus." | ( Koay, ES; Loh, TP; Tambyah, PA; Tang, JW, 2012) |
| "Patients diagnosed with influenza by rapid diagnostic kit underwent treatment in one of the following groups: Maoto-treated group (group 1 (M)); oseltamivir-treated group (group 2 (O)); Maoto+oseltamivir-treated group (group 3 (M+O)); zanamivir-treated group (group 4 (Z)); and Maoto+zanamivir-treated group (group 5 (M+Z))." | ( Kamei, T; Mazda, O; Murata, K; Suzuki, N; Takahashi, I; Toriumi, Y, 2012) |
| "Previously influenza with high temperature, headache and vomiting had occurred and been treated with acetylsalicylic acid for some days." | ( Böhm, M; Kaplan, BT; Link, A, 2012) |
| "A teenager who acquired 2009 H1N1 influenza A lower respiratory tract infection during total bone marrow and lymphoid aplasia, in the setting of human leukocyte antigen-haploidentical hematopoietic stem cell transplantation, was successfully treated with intravenous zanamivir." | ( Adams, O; Borkhardt, A; Ghosh, S; Meisel, R; Schuster, FR, 2012) |
| "At the time of the influenza A(H1N1)pmd09 pandemic it was not known if concurrent or sequential administration of seasonal trivalent influenza vaccine (TIV) with pandemic vaccine was preferred." | ( Chu, L; Frenette, L; Halperin, S; Langley, JM; Li, P; McNeil, S; Vaughn, D, 2012) |
| "During three interpandemic influenza seasons, 137 patients hospitalized with suspected acute influenza were randomized to 5-day treatment with intravenous peramivir 400 mg or 200 mg once daily or oral oseltamivir 75 mg twice daily." | ( Alexander, WJ; Clezy, K; Collis, PJ; Flynt, A; Hui, DS; Ison, MG; O'Neil, BJ; Simon, TJ, 2013) |
| "Titres of influenza A viruses in nasopharyngeal specimens decreased similarly across treatments, but more rapid decreases in titres of influenza B occurred with peramivir treatment." | ( Alexander, WJ; Clezy, K; Collis, PJ; Flynt, A; Hui, DS; Ison, MG; O'Neil, BJ; Simon, TJ, 2013) |
| "Treatment of acute seasonal influenza in hospitalized adults with either peramivir or oseltamivir resulted in generally similar clinical outcomes." | ( Alexander, WJ; Clezy, K; Collis, PJ; Flynt, A; Hui, DS; Ison, MG; O'Neil, BJ; Simon, TJ, 2013) |
| "She was tested positive for influenza A (H1N1) and successfully treated with oral oseltamivir." | ( Ersbøll, AS; Hedegaard, M; Hesselvig, AB; Krebs, L, 2012) |
| "Models of influenza transmission have focused on the ability of vaccination, antiviral therapy, and social distancing strategies to mitigate epidemics." | ( Adida, E; Jones, RM, 2013) |
| "These results suggest that both influenza B virus infection and steroid administration increased the number of circulating Tregs, thus leading to the remission of INS." | ( Kaneko, K; Kimata, T; Kino, J; Kitao, T; Tsuji, S; Yamanouchi, S, 2013) |
| "One patient with 2009 influenza A/H1N1 receiving OSL monotherapy developed confirmed OSL resistance during treatment." | ( Boeckh, MJ; de Jong, MD; Englund, JA; Lindegardh, N; Nguyen, JT; Pukrittayakamee, S; Renaud, C; Seo, S; Tambyah, PA; Tarning, J; Went, GT, 2013) |
| "The risks for severe influenza and fatal outcome include lymphopenia, older age, influenza soon after transplantation or chemotherapy, steroid treatment, and lack of early antiviral therapy." | ( Cordonnier, C; de la Camara, R; Engelhard, D; Ljungman, P; Mohty, B, 2013) |
| "Among Influenza neuraminidase inhibitors (NAIs), oseltamivir corresponds to the most widely used agent to treat influenza disease." | ( Bâ, M; Dia, N; Diadhiou, SA; Diop, OM; Faye, A; Goudiaby, DG; Kiori, D; Michel, R; Niang, MN, 2013) |
| "Presently, the resistance of Influenza A virus isolates causes great difficulty for the prevention and treatment of influenza A virus infection." | ( Chen, S; Liu, Q; Wang, D; Wang, S; Zhang, Y, 2013) |
| "The appearance of influenza virus strains that are resistant to current treatment options demonstrates the need for new antiviral strategies." | ( Haasbach, E; Hartmayer, C; Planz, O, 2013) |
| "Here, we report the recovery of three influenza B viruses with reduced susceptibilities to NA inhibitors from human patients with no history of antiviral drug treatment." | ( Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Sato, H; Takashita, E; Taniwaki, T; Tashiro, M; Xu, H; Yokoyama, M, 2013) |
| "There were no associations between influenza attacks and RA disease activity, treatment with methotrexate (MTX) or corticosteroids." | ( Inoue, E; Kobashigawa, T; Momohara, S; Nakajima, A; Tanaka, E; Taniguchi, A; Yamanaka, H, 2013) |
| "The majority of influenza A(H1N1)pdm09 RT-PCR-positive NPFS samples (n = 1273) were taken after oseltamivir treatment had begun." | ( Andrews, N; Bermingham, A; Durnall, H; Elliot, AJ; Ellis, J; Fleming, D; Galiano, M; Lackenby, A; Large, S; Powers, C; Smith, G; Thompson, C; Zambon, M, 2013) |
| "In the early stages of an evolving influenza epidemic when oseltamivir stocks are low, oseltamivir treatment for influenza can be streamlined and offered to those at highest risk who are under 2 years old or have significant comorbidity to prevent complicated disease." | ( Chong, CY; Fu, S; Menon, A; Tan, NW; Tee, NW; Thoon, KC, 2013) |
| "Conventional treatments against influenza include two classes of pathogen-targeting antivirals: M2 ion channel blockers (such as amantadine) and neuraminidase inhibitors (such as oseltamivir)." | ( Chen, HW; Cheng, JX; King, K; Liu, MT; Liu, YT; Peng, JY; Schooley, RT; Shresta, S; Wang, CH; Zhang, XQ, 2013) |
| "Treatment of influenza with OSV and ZNV for 5 days attenuated the induction of anti-viral S-IgA in nasal washes and anti-viral IgG in serum, compared with the untreated group." | ( Arai, M; Hirotsu, N; Iwaya, M; Kido, H; Mino, M; Mizuno, D; Nishikawa, K; Sawabuchi, T; Shibao, K; Shinahara, W; Shindo, S; Suzuki, S; Takahashi, E; Takasaki, Y; Yamashita, Y; Yokoyama, T, 2013) |
| "Therefore, inhibition of influenza A virus infection by uridine derivatives of 2-deoxy sugars, acting as glycosylation inhibitors, is a promising alternative approach for the development of new anti-influenza A therapy." | ( Gromadzka, B; Krol, E; Matlacz, M; Nidzworski, D; Rychlowska, M; Szewczyk, B; Tyborowska, J; Wandzik, I, 2013) |
| "Administration of influenza vaccines has been associated with the development of autoantibodies and autoimmune rheumatic disease." | ( Carter-Monroe, N; Duggal, T; Geetha, D; Manoharan, P; Segal, P; Shah, M, 2013) |
| "When the influenza A (H1N1) pandemic spread across the globe from April 2009 to August 2010, many WHO Member States used antiviral drugs, specifically neuraminidase inhibitors (NAIs) oseltamivir and zanamivir, to treat influenza patients in critical condition." | ( Hubbard, RJ; Li, J; Meyer, AE; Miller, PE; Mounts, AW; Penn, CR; Rambachan, A; Rolfes, MA; Stephens, P, 2013) |
| "It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options." | ( Barnard, DL; Furuta, Y; Gowen, BB; Shiraki, K; Smee, DF; Takahashi, K, 2013) |
| "During pandemic of influenza A (H1N1) in 2009 the relationship between mortality and medical errors, especially delayed antiviral treatment initiation, was highlighted in many studies." | ( Jurek, T; Rorat, M, 2013) |
| "Seven hundred eighty-four influenza cases aged <18 years hospitalized in ICUs had information on treatment." | ( Louie, JK; Samuel, MC; Schechter, R; Uyeki, TM; Yang, S, 2013) |
| "Few anti-influenza drugs are licensed in the United States for the prevention and therapy of influenza A and B virus infections." | ( Barnard, DL; Furuta, Y; Hurst, BL; Smee, DF; Tarbet, EB; Vollmer, AH, 2014) |
| "Administration of the adjuvant influenza vaccine has been suspected to increase the risk of allograft rejection; however, not much is known about the effect of adjuvant H1N1 vaccination on allograft kidney function." | ( Masoumi, R; Moghaddasi, S; Nouri-Majalan, N, 2013) |
| "Of 27 patients with influenza B virus infection, 8 and 9 were treated with oseltamivir and zanamivir, respectively, whereas 10 received no NAI." | ( Hashimoto, K; Honzumi, K; Hosoya, M; Kawasaki, Y; Miyazaki, K; Sato, M; Sato, T; Watanabe, M, 2014) |
| "An immunocompromised child with influenza A/H3N2 virus infection, treated with oseltamivir from day 1, had nasal swabs taken on days 1, 4, 7, and 10 of the illness." | ( Koay, ES; Kong, DH; Lau, YW; Lee, HK; Loh, TP; Tang, JW; Yap, HK, 2014) |
| "Of etiotropic treatment of influenza and other ARVI include a wide spectrum of antiviral drugs, among which are the drugs with a restricted spectrum, basically used in influenza, and a general spectrum used in influenza and other ARVI as a prophylactic or therapeutic intention." | ( Kramarev, SA; Moshchich, AP, 2013) |
| "The diagnosis of influenza led to stopping antibiotics (n=4), initiating curative (n=4) and preventive (n=4) treatments with oseltamivir, and isolating patients to prevent a hospital outbreak." | ( de Briel, D; Heller, R; Martin, A; Martinot, M; Mohseni-Zadeh, M; Mothes, A; Sagot, E; Souply, L, 2014) |
| "In the 2009-10 influenza season, the safety and immunogenicity of co-administered non-adjuvanted seasonal and MF59-adjuvanted pandemic influenza vaccines were evaluated in this study in 30 RA patients under therapy with anti-tumour necrosis factor (TNF)-α agents or Abatacept and in 13 healthy controls (HC)." | ( Biselli, R; Caporuscio, S; Cappella, A; Crialesi, D; D'Amelio, R; Di Martino, A; Donatelli, I; Facchini, M; Ferlito, C; Germano, V; Milanetti, F; Nisini, R; Rossi, F; Salemi, S, 2014) |
| "We screened the inhibitors of influenza A virus by infecting HeLa-IAV-Luc cells with influenza A virus WSN/H1N1 and treating it with the compounds isolated from microbial metabolites." | ( Lai, W; Wang, S; Ye, X, 2013) |
| "However, the recurrence rate of influenza infection after treatment was significantly reduced in patients who received laninamivir compared with that in those who received oseltamivir and zanamivir (P<0." | ( Kanda, T; Mizuno, S; Mizuno, T, 2014) |
| "She was diagnosed as having influenza encephalopathy presenting non-convulsive status epilepticus (NCSE), and commenced methylprednisolone pulse therapy followed by prednisolone with gradual tapering." | ( Kira, J; Oyagi, Y; Shigetou, H; Tateishi, T; Uehara, T; Une, H, 2014) |
| "In laboratory-confirmed influenza infection, treatment was continued and serial weekly swabs were performed until virologic results were negative." | ( Benden, C; Boeni, J; Isenring, BD; Jungo, C; Kohler, M; Mueller, NJ; Schuurmans, MM, 2014) |
| "In this study, PVS of influenza virus was detected in the majority of LTRs and high VL at diagnosis was predictive for prolonged shedding, which occurred despite extended antiviral therapy." | ( Benden, C; Boeni, J; Isenring, BD; Jungo, C; Kohler, M; Mueller, NJ; Schuurmans, MM, 2014) |
| "Time to first alleviation of symptoms, influenza outcomes, complications, admissions to hospital, and adverse events in the intention to treat population." | ( Doshi, P; Heneghan, CJ; Jefferson, T; Jones, M; Onakpoya, I; Spencer, EA, 2014) |
| "Time to first alleviation of symptoms, influenza outcomes and complications, admissions to hospital, and adverse events in the intention to treat (ITT) population." | ( Heneghan, CJ; Jefferson, T; Jones, M; Onakpoya, I; Spencer, EA; Thompson, M, 2014) |
| "Pregnant women with suspected H1N1 influenza should be started on antiviral therapy at the earliest." | ( Arora, R; Jain, A; Punia, N; Sarda, N; Singhal, S, 2014) |
| "We assigned 191 patients with influenza to 4 groups, each treated with a different NAI, and then compared how long it took to alleviate fever and other symptoms and to eliminate the virus." | ( Asai, T; Ichikawa, M; Ikezoe, I; Matsumoto, J; Miyagawa, S; Takemoto, Y; Yano, T, 2013) |
| "IgM- and IgG influenza-specific antibodies increase after vaccination in HC and RA patients except in patients on RTX treatment." | ( Bijl, M; de Haan, A; Horst, G; Land, J; van Assen, S; Westra, J; Wilting, KR, 2014) |
| "The use of oseltamivir to treat influenza increased markedly in all population groups during the A/H1N1pdm09 pandemic, including pregnant women." | ( Chandrasekaran, A; Tomianovic, D; Wollenhaupt, M, 2014) |
| "Patients hospitalized with suspected influenza were randomized to 5-day treatment with intravenous peramivir (600 mg once daily) or placebo; all received the institution's standard of care (SOC) treatment." | ( Clark, C; Collis, P; de Jong, MD; Elder, J; Ison, MG; McCullough, A; Metev, H; Monto, AS; O'Neil, B; Sheridan, WP, 2014) |
| "Current influenza treatment options include oral or inhaled antiviral agents." | ( Alexander, WJ; Carson, S; Collis, P; Dobo, S; Elder, J; Laughlin, A; Mitha, E; Sheridan, WP; Stich, M; Tellier, G; Whitley, R, 2015) |
| "Peramivir, a parenteral influenza neuraminidase inhibitor (NAI), was administered by single-dose intramuscular (IM) injection in two placebo-controlled studies in adult outpatients with acute, uncomplicated influenza during two consecutive influenza seasons." | ( Alexander, WJ; Carson, S; Collis, P; Dobo, S; Elder, J; Laughlin, A; Mitha, E; Sheridan, WP; Stich, M; Tellier, G; Whitley, R, 2015) |
| "The proportion of subjects shedding influenza virus was significantly decreased over 48 h following peramivir treatment (P=0." | ( Alexander, WJ; Carson, S; Collis, P; Dobo, S; Elder, J; Laughlin, A; Mitha, E; Sheridan, WP; Stich, M; Tellier, G; Whitley, R, 2015) |
| "Although oseltamivir is a common influenza treatment, there is a lack of data on the economic benefits of timely oseltamivir treatment." | ( Aiello, AE; Chung, E; Foxman, B; Jang, GY; Kilgore, PE; Kim, YK; Letson, GW; Lim, JK; Song, YH, 2015) |
| "Rapid influenza diagnostic test was used in a significantly lower proportion of patients treated with oseltamivir ≥ day 3 of admission compared with those who received oseltamivir earlier." | ( Aiello, AE; Chung, E; Foxman, B; Jang, GY; Kilgore, PE; Kim, YK; Letson, GW; Lim, JK; Song, YH, 2015) |
| "Before the 2009 influenza pandemic, dosing guidelines did not exist for patients receiving continuous renal replacement therapy (CRRT)." | ( Bentley, ML; Cain, JS; Hansenb, AC; Hollistera, AS; Smith, JA, 2014) |
| "We compared characteristics of influenza A outbreaks that occurred during 2011/2012 influenza season in three NHs of similar size (208, 167, and 164 residents in NH1, NH2, and NH3, respectively) implementing comparable treatment approaches and non-pharmacological outbreak control measures but different prophylactic pharmacological interventions including oseltamivir 75 mg o." | ( Gorišek Miksić, N; Lobnik Rojko, P; Lusa, L; Petrovec, M; Simonović, Z; Strle, F; Uršič, T, 2015) |
| "We recommend influenza vaccination and early antiviral treatment for at-risk populations." | ( Chang, CH; Chuang, JH; Hsu, YF; Huang, WT, 2015) |
| "There is an unmet need for a parenteral influenza antiviral therapy to treat hospitalized patients." | ( Furukawa, H; Murayama, M; Soutome, T; Watanabe, A; Yates, PJ, 2015) |
| "Patients hospitalized with influenza were treated with IVZ 600 mg twice daily for five days." | ( Furukawa, H; Murayama, M; Soutome, T; Watanabe, A; Yates, PJ, 2015) |
| "The sequential influenza viral RNA load and susceptibility after peramivir administration were measured using a quantitative real-time reverse transcription-PCR and neuraminidase inhibition assay." | ( Hashimoto, K; Hosoya, M; Ito, M; Kawasaki, Y; Miyazaki, K; Oda, S; Sakuma, H; Sato, M; Suzuki, S; Takeyama, A; Watanabe, M, 2015) |
| "Mice were infected with HINI strain of influenza and then challenged with cMRSA at day 7, treated with antibiotics (LZD or Vanco) or vehicle 6 hours post bacterial challenge and lungs and bronchoalveolar lavage fluid (BAL) harvested at 24 hours for bacterial clearance, inflammatory cell influx, cytokine/chemokine analysis and assessment of lung injury." | ( Ballinger, MN; Bhan, U; Keshamouni, V; Kovach, MA; Podsiad, AB; Standiford, TJ, 2015) |
| "Rapid and accurate diagnosis of influenza is necessary for appropriate patient management during the influenza season and for optimal utilization of anti-influenza therapy." | ( de Lazzari, E; de Molina, P; Estape, JV; Hurtado, JC; Isanta, R; Marcos, MA; Martínez, E; Mosquera, MM; Pumarola, T; Torner, N; Vila, J, 2015) |
| "The results indicate that resistance in influenza viruses infecting humans is due to the selection pressure posed by the global OE administration in humans rather than transfer from avian influenza A virus strains carrying mutations induced by environmental exposure to OC." | ( Lindh, M; Norberg, P; Olofsson, S, 2015) |
| "We therefore diagnosed him with primary influenza pneumonia and initiated treatment with peramivir plus corticosteroids, which rapidly improved his condition." | ( Nishi, K; Nishitsuji, M; Ohkura, N; Tani, M, 2015) |
| "Six patients had influenza detected on or after day 11 of treatment." | ( Anderson, EJ; Clinch, B; Deville, JG; Kamal, MA; Muñoz, FM, 2015) |
| "HI titers against both influenza A strains as well as memory B-cell response were modestly higher in the antihelminthic treated group compared to the placebo group but the difference was not statistically significant." | ( Adegnika, AA; Agnandji, ST; Bache, E; Berberich, S; Brückner, S; Engleitner, T; Esen, M; Fernandes, JF; Kremsner, PG; Lell, B; Massinga Loembe, M; Mordmüller, B; Schweiger, B; Yazdanbakhsh, M, 2015) |
| "Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy." | ( Boucher, CA; Cowling, BJ; Ip, DK; Schutten, M; Tong, X; van der Vries, E; Wojtowicz, K; Zhang, JD, 2016) |
| "During the influenza A/H1N1 pandemic in 2009, early prompt antiviral therapy may have reduced the severity of the influenza outcomes including pneumonia, hospitalization and mortality in the Republic of Korea." | ( Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY, 2015) |
| "A 9-year-old girl developed influenza A H1N1 pdm09-associated myocarditis and pericarditis 2 days after starting zanamivir therapy." | ( Aoyagi, Y; Chishiki, M; Endo, K; Hosoya, M; Ito, N; Kawasaki, Y; Momoi, N; Sato, M, 2015) |
| "Surveillance of circulating influenza strains for antiviral susceptibility is important to ensure patient treatment guidelines remain appropriate." | ( Baas, C; Barr, IG; Butler, J; Harrower, B; Hurt, AC; Leang, SK; Little, K; Mosse, J, 2015) |
| "Oseltamivir is the influenza virus drug that is most commonly studied in children for both the treatment and prevention of influenza." | ( Esposito, S; Principi, N, 2016) |
| "The treatment of influenza-infected patients within 48h of symptom onset with oseltamivir and umifenovir was associated with a significant decrease in the duration of illness (2-3 days) and symptoms (p<0." | ( Burtseva, EI; Fedyakina, IT; Kirillova, ES; Leneva, IA; Maleev, VV; Osipova, E; Selkova, EP; Yatsyshina, SB, 2016) |
| "Since the novel H7N9 avian influenza outbreak occurred in China in 2013, neuraminidase inhibitors (NAIs) such as oseltamivir and peramivir have been used as first-line drugs to treat the influenza virus infection." | ( Chen, P; Gao, H; Li, L; Liang, W; Ou, H; Tang, L; Wu, X; Yang, Y; Yu, L; Zhang, Y; Zheng, S, 2016) |
| "Patients with severe influenza virus infection, multi-organ failure and organ replacement therapy may absorb and metabolize neuraminidase inhibitors differently." | ( Amann, V; Berger, F; Chen, X; de Zwart, M; Duwe, S; Fraaij, P; Francis, RC; Heider, A; Karsch, K; Miera, O; Obermeier, P; Osterhaus, A; Peters, B; Rath, B; Schweiger, B, 2017) |
| "Patients with 2009 pandemic influenza A(H1N1pdm09)-related critical illness were frequently treated with systemic corticosteroids." | ( Adhikari, NK; Burns, KE; Burry, LD; Cook, DJ; Delaney, JW; Ferguson, ND; Fowler, RA; Griesdale, D; Hutchison, J; Jouvet, P; Kumar, A; Lamontagne, F; Long, J; Marshall, JC; Mehta, S; Menon, K; Pinto, R, 2016) |
| "In this report, we show that influenza virus downregulates the unfolded protein response mediated by the PERK sensor, while Montelukast, a drug used to treat asthma in humans, specifically stimulated this response and downregulated viral protein synthesis and multiplication." | ( Falcón, A; Fernández, Y; Landeras-Bueno, S; Oliveros, JC; Ortín, J, 2016) |
| "The development of treatments for influenza that inhibit the M2 proton channel without being susceptible to the widespread resistance mechanisms associated with the adamantanes is an ongoing challenge." | ( Agafitei, O; Arns, S; Balgi, AD; Bourque, E; Jaquith, JB; Kumar, N; Niikura, M; Pfeifer, TA; Roberge, M; Shidmoossavee, FS; Shimizu, Y; Sun, S; Tai, SS, 2016) |
| "A debate about the market-leading influenza antiviral medication, oseltamivir, which initially focused on treatment for generally mild illness, has been expanded to question the wisdom of stockpiling for use in future influenza pandemics." | ( Hurt, AC; Kelly, H, 2016) |
| "Peramivir, the only injectable anti-influenza neuraminidase inhibitor medically available in Japan at present, is considered first-line treatment in patients with high risk factors for influenza exacerbation." | ( Ishii, S; Itoh, Y; Komeda, T; Sanekata, M; Shimada, J; Yoshikawa, T, 2016) |
| "Treatment of influenza virus infection with oral oseltamivir reduces time to alleviation of symptoms in adults and children by approximately one day compared with placebo." | ( Broadhurst, R; Mounsey, A, 2016) |
| "Causal treatment can be given for influenza, using a neuraminidase inhibitor, and respiratory syncytial virus, using ribavirin in addition to intravenous immunoglobulins." | ( Berger, A; Christopeit, M; Hauf, E; Hentrich, M; Heussel, CP; Kalkreuth, J; Klein, M; Kochanek, M; Lehners, N; Mayer, K; Penack, O; Rieger, C; Schalk, E; Silling, G; Vehreschild, M; von Lilienfeld-Toal, M; Weber, T; Wolf, HH, 2016) |
| "Among the 217 patients with influenza A(H3N2) enrolled, 107 were randomly assigned to the combination treatment." | ( Chan, JFW; Chan, KH; Chan, TC; Chen, H; Cheng, VCC; Cheung, MKS; Fok, M; Hung, IFN; Lau, JYN; Leung, W; Li, P; Liu, KSH; Tam, A; To, KKW; Wong, TL; Yuen, KY; Zhang, AJ; Zhang, R, 2017) |
| "Treatment increased after the influenza A(H1N1) 2009 pandemic from 72% in 2010-2011 to 89% in 2014-2015 (P < ." | ( Anderson, E; Appiah, GD; Bargsten, M; Bennett, N; Brady, D; Campbell, AP; Chaves, SS; Eckel, S; Fry, AM; Garg, S; Hill, M; Kirley, PD; Lindegren, ML; Lung, K; Lynfield, R; McDonald-Hamm, C; Meek, J; Miller, L; Oni, O; Ryan, P; Schaffner, W; Thomas, A; Zansky, SM, 2017) |
| "Infants exhibit elevated influenza virus loads and prolonged viral shedding, which may increase the risk for resistance development, especially in cases of suboptimal exposure to antiviral therapy." | ( Chen, X; Duwe, SC; Karsch, K; Milde, J; Muehlhans, S; Obermeier, P; Rath, B; Schweiger, B; Seeber, L; Skopnik, H; Spies, V; Tief, F, 2017) |
| "The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat." | ( Hurst, BL; Morçӧl, T; Tarbet, EB, 2017) |
| "Children with severe influenza infection may require parenteral therapy if oral or inhaled therapies are ineffective or cannot be administered." | ( Adams, B; Blumer, JL; Bradley, JS; DeBiasi, RL; Hossain, M; Kimberlin, DW; Michaels, MG; Munoz, FM; Pahud, B; Peppercorn, A; Roberts, G; Romero, JR; Shortino, D; Yamamoto, G; Yates, PJ, 2017) |
| "Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous haemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands." | ( Favié, LM; Meijer, A; Murk, JL; Nijstad, AL; Sikma, MA; van Maarseveen, EM, 2018) |
| "Serum interleukin (IL)-6 levels in influenza-A-infected children significantly decreased after peramivir administration, unlike in those with influenza B where a decrease on day 1 was followed by an increase on day 2." | ( Hashimoto, K; Hosoya, M; Kawasaki, Y; Sato, M, 2018) |
| "Antiviral treatment of influenza virus infections can lead to drug resistance of virus." | ( Christiansen, CB; Fischer, TK; Trebbien, R, 2018) |
| "The treatment of influenza A (H1N1) is mainly antiviral treatment, symptomatic treatment or traditional Chinese medicine treatment." | ( Dai, H; Lu, Y; Ma, L; Mu, X; Wang, Y; Yao, J; Yu, P; Zhang, H, 2018) |
| "Over multiple influenza seasons, early NAI therapy was associated with shorter LOS in patients admitted with influenza." | ( Houk, JL; Ison, MG; Katzen, J; Kohn, R, 2019) |
| "New and efficient treatments against influenza in immunocompromised patients are needed." | ( Escuret, V; Gaymard, A; Javouhey, E; Josset, L; Lina, B; Malcus, C; Massenavette, B; Millat, G; Monneret, G; Morfin-Sherpa, F; Picard, C; Pichon, M; Renard, C; Simon, B; Valette, M, 2018) |
| "We compared the rate of influenza infection during the 2016-2017 season (8 months, from October 2016-May 2017) between KTx patients treated with 1 or 2 doses of influenza vaccine (treatment group, n = 71) and KTx patients who did not receive a vaccine (nontreatment group, n = 27)." | ( Chinen, K; Iseki, K; Ishida, H; Nagayama, K; Oroku, M; Ota, M; Shiohira, Y; Tanabe, K; Tsujimura, K, 2018) |
| "However, novel influenza variants exhibiting over 10-fold reductions in baloxavir susceptibility emerged in baloxavir-treated patients." | ( Kikuchi, T; Watanabe, A, 2019) |
| "Patients hospitalized for influenza should receive early treatment with a neuraminidase inhibitor." | ( De Briel, D; Gerber, V; Greigert, V; Gronnwald, A; Martinot, M; Mohseni Zadeh, M; Rosolen, B; Thibaud, E, 2019) |
| "Among patients with influenza A/H3N2, early treatment was associated with significantly lower mortality (relative risk, 0." | ( Andreopoulou, A; Bonovas, S; Lytras, T; Mouratidou, E; Tsiodras, S, 2019) |
| "Severely ill patients with suspected influenza should be promptly treated with oseltamivir, particularly when A/H3N2 is circulating." | ( Andreopoulou, A; Bonovas, S; Lytras, T; Mouratidou, E; Tsiodras, S, 2019) |
| "No difference was found between anti-influenza drugs treated and non-treated patients." | ( Sato, D; Takeuchi, S; Tetsuhashi, M, 2019) |
| "Human infections with avian-origin influenza A(H7N9) virus represent a serious threat to global health; however, treatment options are limited." | ( Ando, Y; Kawai, M; Kida, H; Kobayashi, M; Matsuno, K; Naito, A; Nobori, H; Noshi, T; Okamatsu, M; Sakoda, Y; Sato, A; Shishido, T; Taniguchi, K; Toba, S; Yoshida, R, 2019) |
| "Oseltamivir can be used to treat influenza." | ( Helve, O; Kaila, M; Mukka, M; Mustonen, P; Pesälä, S; Virtanen, MJ; Ylilammi, K, 2019) |
| "Our lead compound neutralizes influenza A group 1 viruses by inhibiting HA-mediated fusion in vitro, protects mice against lethal and sublethal influenza challenge after oral administration, and effectively neutralizes virus infection in reconstituted three-dimensional cell culture of fully differentiated human bronchial epithelial cells." | ( Blokland, S; Brandenburg, B; Buyck, C; Dhanak, D; Friesen, RHE; Garg, D; Goudsmit, J; Goutier, W; Jonckers, THM; Jongeneelen, M; Juraszek, J; Kadam, RU; Klap, JM; Koudstaal, W; Lanckacker, E; Lawson, E; Peeters, DCG; Raboisson, P; Roevens, P; Roymans, D; Schepens, WBG; Schmitz, F; Stoops, B; Tang, C; van Diepen, HA; van Dongen, MJP; van Eijgen-Obregoso Real, A; Vermond, J; Vogels, R; Wilson, IA; Wu, J; Yu, W, 2019) |
| "With this new class of influenza drug comes exciting prospects for combination therapy with the neuraminidase inhibitors which may help to abate concerns about the development of resistance." | ( O'Hanlon, R; Shaw, ML, 2019) |
| "Rapid diagnosis of influenza is important for early treatment and institution of control measures." | ( Chan, YF; Chong, YM; Hooi, PS; Lee, LM; Sam, IC; Tan, XH, 2019) |
| "The incidences of AKI in Influenza-A H1N1 treated with antiviral and antibiotic combination was statistically less as compared to patients who were given antiviral alone for treatment of influenza infection." | ( Al Nami, H; Alsultan, MT; Ishaqui, AA; Khan, AH; Khan, I; Syed Sulaiman, SA, 2019) |
| "Limited treatment options for severe influenza pneumonia prioritize the need for the discovery of effective therapies." | ( Alcorn, JF; Cipriani, A; Hebert, KD; Mclaughlin, N; Pociask, DA; Zhang, Z, 2019) |
| "In 2019, influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic gene, which confers reduced susceptibility to baloxavir, were detected in Japan in an infant without baloxavir exposure and a baloxavir-treated sibling." | ( Abe, T; Akimoto, M; Fujisaki, S; Hasegawa, H; Ichikawa, M; Kishida, N; Kuwahara, T; Mitamura, K; Miura, H; Morita, H; Nakamura, K; Odagiri, T; Ogawa, R; Sato, A; Shirakura, M; Sugawara, H; Takashita, E; Watanabe, S; Yamazaki, M, 2019) |
| "Here we report the isolation of the influenza A/H1N1 2009 pandemic (A/H1N1pdm) and A/H3N2 viruses carrying an I38T mutation in the polymerase acidic protein-a mutation that confers reduced susceptibility to baloxavir marboxil-from patients before and after treatment with baloxavir marboxil in Japan." | ( Adachi, E; Dutta, J; Hagiwara, H; Hasegawa, H; Imai, M; Ito, M; Iwatsuki-Horimoto, K; Izumida, N; Jubishi, D; Kawaoka, Y; Khan, Z; Kiso, M; Koga, M; Kriti, D; Kuroki, H; Lopes, TJS; Murakami, J; Nakajima, N; Nishino, T; Sakai-Tagawa, Y; Takada, K; Takahashi, K; Tokita, A; van Bakel, H; Wada, N; Yamashita, M; Yasuhara, A, 2020) |
| "Primary care patients with influenza-like illness treated with oseltamivir recovered one day sooner on average than those managed by usual care alone." | ( Aabenhus, R; Bjerrum, L; Bongard, E; Bucher, HC; Butler, CC; Chlabicz, S; Coenen, S; Colliers, A; Connor, JT; Cook, J; de Jong, MD; De Sutter, A; Francis, NA; Glinz, D; Godycki-Cwirko, M; Goossens, H; Holmes, J; Ieven, M; Jonassen Harbin, N; Kovács, B; Lewis, RJ; Lindbæk, M; Lionis, C; Little, P; Llor, C; Matheeussen, V; Murphy, AW; Openshaw, P; Radzeviciene Jurgute, R; Saville, BR; Seifert, B; Sundvall, PD; Touboul Lundgren, P; van der Velden, AW; Verheij, TJ, 2020) |
| "Treating influenza with oseltamivir does not increase the risk of NPEs." | ( Hong, J; Huh, K; Jung, J; Kang, M; Shin, DH, 2020) |
| "He was also tested positive for influenza A (H1N1) and received treatment with oral oseltamivir without any clinical benefit." | ( Samaddar, A; Sharma, A; Shrimali, T, 2020) |
| "In 2018, the first mechanistically new influenza drug class for the treatment of uncomplicated seasonal influenza in 2 decades was approved for human use." | ( Plemper, RK; Toots, M, 2020) |
| "MHAA4549A is a human anti-influenza A monoclonal antibody developed to treat influenza A." | ( Castro, A; Deng, R; Hanley, WD; Horn, P; Kulkarni, P; Lim, JJ; Maia, M; McBride, JM; Newton, E; Peck, MC; She, G; Tavel, JA, 2020) |
| "Treatments against influenza A viruses (IAV) have to be updated regularly due to antigenic drift and drug resistance." | ( Du, J; Liu, W; Ren, X; Wang, Q; Zhang, Y, 2021) |
| "As the burden of influenza disease is substantial and oseltamivir treatment is biologically plausible, this study assessed the clinical benefit of oseltamivir treatment in adult patients admitted with severe seasonal influenza virus infection in daily practice." | ( de Boer, MGJ; de Vries, JJC; Groeneveld, GH; Ismail, N; Marbus, SD; Oosterheert, JJ; Schneeberger, P; van Dissel, JT, 2020) |
| "During the 2015-16 and 2016-17 influenza seasons, adult patients in two US EDs were randomized to either oral oseltamivir or IV peramivir treatment group." | ( Dugas, AF; Hsieh, YH; LoVecchio, F; McBryde, B; Ricketts, EP; Rothman, RE; Saliba-Shaw, K, 2021) |
| "Clinical outcomes of influenza-infected patients treated with single-dose IV peramivir were comparable to those treated with oral oseltamivir, suggesting potential utility of peramivir for influenza-infected patients in the ED." | ( Dugas, AF; Hsieh, YH; LoVecchio, F; McBryde, B; Ricketts, EP; Rothman, RE; Saliba-Shaw, K, 2021) |
| "The study aims to test the effect of influenza vaccination on phenytoin, CYP2C9, and IFNγ levels in epileptic patients receiving phenytoin monotherapy METHODS: Thirty-one epileptic patients receiving stable-dose phenytoin monotherapy were enrolled onto the study." | ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Manoyana, N; Nadsasarn, A; Pinyopornpanish, K; Soontornpun, A; Tanprawate, S, 2020) |
| "The administration of influenza vaccine to epileptic patients receiving phenytoin monotherapy appears to be safe." | ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Manoyana, N; Nadsasarn, A; Pinyopornpanish, K; Soontornpun, A; Tanprawate, S, 2020) |
| "To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment." | ( De Vita, S; Gallo, T; Quartuccio, L; Valent, F; Zabotti, A, 2021) |
| "It is also important to minimize influenza morbidity and mortality by vaccinating family members, using empiric therapy, providing immediate antiviral therapy, and educating parents about hygiene measures." | ( Drabko, K; Lejman, M; Zaucha-Prażmo, A; Zawitkowska, J, 2020) |
| "Baloxavir is an efficacious antiinfluenza treatment that may reduce hospitalization compared with oseltamivir and zanamivir." | ( Ajisawa, Y; Fujiwara, M; Hara, K; Honda, K; Hosogaya, N; Iwata, S; Kitanishi, Y; Komeda, T; Miyauchi, H; Miyazaki, T; Mukae, H; Ogura, E; Takazono, T; Watanabe, H, 2021) |
| "Severe influenza cases were treated with oseltamivir in only 45." | ( Botelho-Nevers, E; Cantais, A; Cizeron, A; Gagneux-Brunon, A; Pillet, S; Saunier, F, 2021) |
| "The treatment of influenza with IV peramivir or oral oseltamivir had similar clinical efficacy." | ( Chou, SC; Fang, YH; Hsu, TH; Lin, TY; Liu, CH; Perng, PC; Wu, JY, 2021) |
| "Understanding how influenza viruses traverse the mucus and recognize host cells is critical for evaluating their zoonotic potential, and for prevention and treatment of the disease." | ( Huskens, J; Overeem, NJ; van der Vries, E, 2021) |
| "We aimed to detect influenza variants with reduced susceptibility to baloxavir marboxil (baloxavir) and oseltamivir and identify differences in the clinical course between children with and without these variants after antiviral treatment." | ( Fujisaki, S; Hashimoto, K; Hosoya, M; Katayose, M; Nemoto, K; Sakai, N; Sato, M; Takashita, E, 2021) |
| "During the 2019-2020 influenza season, we enrolled children with confirmed influenza A (20 treated with baloxavir and 16 with oseltamivir)." | ( Fujisaki, S; Hashimoto, K; Hosoya, M; Katayose, M; Nemoto, K; Sakai, N; Sato, M; Takashita, E, 2021) |
| "This study suggests that influenza treatment with baloxavir is cost-effective compared with laninamivir in the adult high-risk population in Japan." | ( Aballéa, S; Ansaripour, A; Dronova, M; Hill, M; Hirotsu, N; Igarashi, A; Ikeoka, H; Itsumura, N; Onishi, Y, 2021) |
| "Oseltamivir treatment of infants with influenza rapidly decreased the viral load in nasopharyngeal secretions and shortened the duration and severity of symptoms." | ( Antikainen, P; Heikkinen, T; Mattila, JM; Vuorinen, T; Waris, M, 2021) |
| "Live Attenuated Influenza Virus (LAIV) is administered to and replicates in the sinonasal epithelium." | ( Liu, H; Pekosz, A; Powell, H, 2021) |
| "Our findings suggest that influenza virus can infect adipose tissue and lead to intestinal adipose immune dysfunction in normal-weight mice and that the impairment of the intestinal and adipose immune response to influenza virus infection can be reversed by puerarin treatment." | ( Liu, JY; Wang, HX; Xu, PP; Yu, WD; Zeng, MS, 2021) |
| "Antiviral treatment of influenza is recommended for patients with influenza-like illness during periods of community cocirculation of influenza viruses and SARS-CoV-2; however, questions remain about which treatment is associated with the best outcomes and fewest adverse events." | ( Chiu, HY; Lee, JA; Lin, SH; Liu, JW; Wang, LC, 2021) |
| "When a patient with an influenza RT-PCR diagnosis was hospitalized in a multiple-bed room, the emergency preventive strategy was applied: selection of non-immunocompromised neighbor, implementation of physical barriers (rigid screen pulled between beds, surgical mask for healthcare workers and visitors), preemptive Oseltamivir therapy for the neighbor." | ( Azzam, O; Buet, E; Cazzorla, F; Gallouche, M; Giner, C; Landelle, C; Larrat, S; Mallaret, MR; Morand, P, 2022) |
| "Diagnosis and treatment of influenza patients are often provided across several medical specialties." | ( Funk, GC; Karolyi, M; Kelani, H; Lindner, B; Omid, S; Pawelka, E; Porpaczy, C; Publig, S; Seitz, T; Traugott, M; Turner, M; Wenisch, C; Zoufaly, A, 2021) |
| "Few therapies exist for treatment of influenza infection, and each require initiation as early as possible in the course of infection, making efficacy difficult to estimate in the hospitalized patient with lower respiratory tract infection." | ( Carrico, RM; Fry, AM; Furmanek, SP; Hoft, D; Peyrani, P; Ramirez, JA; Wiemken, TL, 2021) |
| "Because antiviral treatment for influenza is associated with better health outcomes, further studies of subsequent seasons would help evaluate current use of antivirals among children and better understand barriers for treatment." | ( Azimi, PH; Boom, JA; Campbell, AP; Englund, JA; Haddadin, Z; Halasa, NB; Hamdan, L; Harrison, CJ; Klein, EJ; McNeal, M; Munoz, F; Patel, M; Probst, V; Rahman, H; Sahni, LC; Selvarangan, R; Singer, MN; Spieker, AJ; Staat, MA; Stewart, LS; Szilagyi, PG; Vandekar, S; Weinberg, GA; Williams, JV, 2022) |
| "Among 529 201 influenza episodes, 30 964 were untreated and 498 237 were treated with anti-influenza drugs: baloxavir, 207 630; oseltamivir, 143 722; zanamivir, 28 208; peramivir, 5304; laninamivir, 113 373." | ( Fujiwara, M; Hara, A; Hara, K; Kobayashi, C; Komeda, T; Miyazawa, S; Ogura, E; Urushihara, H; Yoshida, M, 2022) |
| "Most influenza vaccines are administered via intramuscular injection which has several disadvantages that might jeopardize the compliance of vaccinees." | ( Akkerman, R; Beukema, M; Bhide, Y; Bouwstra, JA; de Vries-Idema, JJ; Frijlink, HW; Hinrichs, WLJ; Huckriede, ALW; Jiskoot, W; Lee, J; O'Mahony, C; Tian, Y; van der Maaden, K, 2022) |
| "A positive influenza test result was associated with antiviral treatment, and early treatment was associated with lower mortality, suggesting that more widespread testing might improve patient outcomes." | ( Deshpande, A; Haessler, S; Higgins, T; Imrey, PB; Klompas, M; Lindenauer, PK; Pallotta, AM; Rothberg, MB; Yu, PC; Zilberberg, MD, 2022) |
| "Two patients with influenza-associated ANE were treated." | ( Abe, Y; Hayakawa, I; Ishiguro, A; Okajima, K; Shimura, K; Tsuboi, N, 2022) |
| "Treatment of patients with influenza with single-dose baloxavir was generally associated with lower HCRU and costs post treatment compared with oseltamivir, particularly in high-risk patients." | ( Castro, RC; Chawla, D; Neuberger, E; Wallick, C, 2022) |
| "Safe and effective treatment of influenza is important not only for seasonal influenza infection, but also if a pandemic strain was to emerge." | ( Baz, M; Koszalka, P; Subbarao, K, 2022) |
| "New antiviral influenza treatments can effectively alleviate illness while reducing viral shedding." | ( Chen, D; Jiang, Y; Lin, YF; Shi, S; Shu, Y, 2022) |
| "For influenza virus overall, influenza B virus, and influenza A(H1N1)pdm09 virus, baloxavir treatment resulted in shorter duration of fever than oseltamivir treatment, but not for influenza A virus and influenza A(H3N2) virus." | ( Fujiyasu, H; Kakuya, F; Kinebuchi, T; Kurisawa, MJ; Okubo, H, 2022) |
| "Antiviral drugs are available for influenza, although two of the four FDA-approved antiviral treatments have resulted in significant drug resistance." | ( Kumalo, HM; Mtambo, SE, 2022) |
| "Liposomal influenza vaccines are a promising strategy to overcome these limitations and the use of liposomal immune modulators and intranasal administration of liposomal influenza vaccines may be a means by which to improve influenza protection." | ( Gao, T; Ma, S; Mai, Y; Yang, J; Yu, N; Yu, R, 2022) |
| "Randomized influenza-infected patients were divided into subgroups of interest based on prespecified baseline and infection-related characteristics, as well as randomized treatment arms (intravenous zanamivir 300 mg or 600 mg, or oral oseltamivir 75 mg)." | ( Haesendonckx, S; Leopold, L; Van Dromme, I; van Duijnhoven, W; Witek, J, 2022) |
| "Pandemic influenza CMGs including supportive care or empirical treatment recommendations were included." | ( Balan, V; Blumberg, L; Cai, E; Cheng, V; Dagens, A; Dahmash, D; Groves, H; Harriss, E; Hart, P; Horby, PW; Jacob, S; Joseph, R; Lipworth, S; Michelen, M; Oti, A; Rigby, I; Sigfrid, L, 2022) |
| "Tiliroside is effective for influenza virus infection treatment and promising for further drug development." | ( Cao, F; Huang, T; Liang, W; Liu, B; Shaw, PC; Tang, YS; Xiao, M; Yang, Y; Zhang, T; Zhao, X, 2023) |
| "Tiliroside is effective for influenza virus infection treatment and promising for further drug development." | ( Cao, F; Huang, T; Liang, W; Liu, B; Shaw, PC; Tang, YS; Xiao, M; Yang, Y; Zhang, T; Zhao, X, 2023) |
| "Tiliroside is effective for influenza virus infection treatment and promising for further drug development." | ( Cao, F; Huang, T; Liang, W; Liu, B; Shaw, PC; Tang, YS; Xiao, M; Yang, Y; Zhang, T; Zhao, X, 2023) |
| "Data regarding on-site influenza testing and antiviral treatment within homeless shelters remain limited." | ( Casto, AM; Chu, HY; Englund, JA; Han, PD; Hughes, JP; Link, AC; Martinez, MA; Nackviseth, C; Nwanne, G; Pfau, B; Rogers, JH; Shendure, J; Sugg, N; Uyeki, TM; Wolf, CR, 2023) |
| "Our findings suggest feasibility of influenza test-and-treat strategies in shelters." | ( Casto, AM; Chu, HY; Englund, JA; Han, PD; Hughes, JP; Link, AC; Martinez, MA; Nackviseth, C; Nwanne, G; Pfau, B; Rogers, JH; Shendure, J; Sugg, N; Uyeki, TM; Wolf, CR, 2023) |
| "Anti-influenza treatment is important for children and is recommended in many countries." | ( Fukao, K; Hirotsu, N; Kojima, S; Piedra, PA; Sakaguchi, H; Tsuchiya, K; Uehara, T, 2023) |
| "Treatment-emergent resistant influenza variants may occur during NAI and baloxavir use, but it has no major impact on subsequent recovery." | ( Chan, KKP; Hui, DSC, 2023) |
| "Virus samples were collected twice from influenza rapid test-positive patients at the first and second visit 4-5 days after the start of treatment." | ( Aoki, S; Chon, I; Kakuya, F; Kawashima, T; Kitano, A; Kodo, N; Li, J; Minato, M; Nagata, N; Ono, Y; Phyu, WW; Saito, R; Saito, T; Sato, I; Shimada, Y; Sun, Y; Suzuki, E; Tanaka, T; Wagatsuma, K; Watanabe, H, 2023) |
| "The emergence of 21 PA variants in influenza A was detected after BA treatment, but NA variants were not detected after NAIs treatment." | ( Aoki, S; Chon, I; Kakuya, F; Kawashima, T; Kitano, A; Kodo, N; Li, J; Minato, M; Nagata, N; Ono, Y; Phyu, WW; Saito, R; Saito, T; Sato, I; Shimada, Y; Sun, Y; Suzuki, E; Tanaka, T; Wagatsuma, K; Watanabe, H, 2023) |
| "Participants with acute uncomplicated influenza A treated with pimodivir in the TOPAZ study infrequently developed reduced susceptibility to pimodivir and combining pimodivir with oseltamivir further decreased the risk of reduced susceptibility development." | ( Anderson, D; De Meyer, S; Leopold, L; Van Dromme, I; van Duijnhoven, W; Vingerhoets, J, 2023) |
| "The levels of influenza virus viral RNA (vRNA), complementary RNA (cRNA), and mRNA were specifically reduced in virus-infected cells following STH treatment." | ( Hu, X; Jin, M; Sun, X; Yang, L; Zhang, Q; Zhao, L, 2023) |
| "As a prospective influenza vaccination platform, a microneedle patch offers advantages such as self-administration and reduction of needle-phobia-associated vaccination avoidance." | ( Gill, HS; Joshi, G; Nesovic, LD; Roach, CJ, 2023) |
| "The anti-influenza functions of the DAT producer were evaluated using an antibiotic-treated mouse model by orally administering the specific strain before viral infection." | ( Fang, Z; Lu, W; Wang, H; Wang, Q; Xiao, Y; Zhang, H; Zhang, P; Zhou, X, 2023) |
| "Given the magnitude of influenza pandemics as a threat to the global population, it is crucial to have as many prevention and treatment options as possible." | ( Hao, C; Huang, L; Ma, X; Sun, L; Wang, J; Wang, W, 2023) |